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1.  INTRODUCTION AND BACKGROUND 
 
1.1. Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disorder 
characterised by permanent, progressive, and poorly reversible airflow limitation leading to 
chronic respiratory symptoms - cough, expectoration and dyspnoea. Together with asthma 
COPD is the most common chronic respiratory disease [1]. According to the World Health 
Organization (WHO) COPD was the fourth leading cause of death in 2004, after ischaemic 
heart disease, cerebrovascular disease and lower respiratory infections, and it was estimated 
that by 2030 it will become the third leading cause of death worldwide [2]. With around 384 
million patients in the world, global prevalence of 11.7% in adult population and around three 
million deaths annually, COPD is a leading cause of morbidity and mortality worldwide and 
represents a significant socioeconomic burden [1, 3, 4]. Additionally, the global prevalence 
and burden of COPD are projected to increase in the coming decades due to the continued 
high exposure to risk factors, especially tobacco smoking, and the ageing of the world’s 
population [5]. 
 
1.1.1.  Risk factors 
COPD results from a complex interaction between long-term cumulative exposure to noxious 
gases and particles, combined with different host factors. Cigarette smoking is the leading 
environmental risk factor for COPD, especially in high- and middle-income countries, and is 
also the most studied. Cigarette smokers have a higher prevalence of respiratory symptoms, 
accelerated lung function decline and a greater COPD mortality rate than non-smokers [6]. 
Other types of tobacco (e.g. pipe, cigar, water pipe) and marijuana smoking, as well as 
passive exposure to cigarette smoke also represent risk factors for COPD [7, 8, 9].  
Occupational exposure to organic and inorganic dusts, chemicals and fumes is associated with 
airflow limitation and respiratory symptoms, but is often under-appreciated as a risk factor for 
COPD [10]. In low-income countries exposure to indoor air pollution as a result of the broad 
use of coal and biomass fuels for cooking, heating and other household needs is an important 
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risk factor for COPD, especially for non-smoking women [11]. Outdoor air pollution in urban 
and industrial areas is recognised as harmful to individuals with pre-existing lung disease, but 
its role in the development of COPD is less clear.  
Genetics may play a role in the susceptibility to COPD in individuals with environmental 
exposures. The best documented genetic risk factor is a severe hereditary deficiency of alpha-
1 antitrypsin, a major circulating inhibitor of serine proteases [12]. Other host factors that may 
predispose to the development of COPD include frequent and/or severe lower respiratory 
infections during childhood [13], low birth weight [14], asthma and airway hyper-
responsiveness [15], chronic bronchitis with mucus hypersecretion [16], lower socioeconomic 
status [17], and HIV infection [18].  
Age is often considered a risk factor for COPD, although it is not clear whether age really 
represents an independent risk factor or it actually reflects the cumulative exposures to 
environmental factors throughout one’s life [19]. COPD prevalence and mortality were higher 
in men for a long time, but recent studies from developed countries report an equal prevalence 
of COPD in men and women, probably reflecting the increase in cigarette smoking among 
women in the last decades [20]. 
 
1.1.2.  Pathogenesis and pathophysiology 
Prolonged or repeated inhalation of toxic particles and gases in a genetically predisposed 
individual leads to the development of chronic inflammation in the lungs. Increased numbers 
of macrophages, activated neutrophils, and different subtypes of lymphocytes can be found in 
peripheral airways, lung parenchyma, and the pulmonary vessels of patients with COPD [21]. 
In some patients who demonstrate clinical overlap with asthma there may also be increased 
numbers of eosinophils in the airways. All these inflammatory cells, together with epithelial 
cells are involved in the production and release of multiple inflammatory mediators (e.g. 
proinflammatory cytokines, chemoattractants, growth factors), oxidants and different types of 
proteinases (e.g. elastase, cathepsin G, proteinase 3, matrix metalloproteinase) leading to 
various aspects of tissue damage [22]. Oxidative stress and protease-antiprotease imbalance 
may have a key role in driving lung inflammation and parenchymal tissue destruction 
resulting in the development of emphysema and the reduction of gas-exchanging surface of 
the lung [23]. On the other hand, excessive defence and repair mechanisms result in lung 
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remodelling, inflammatory and/or fibrous thickening and narrowing of small bronchioles 
leading to progressive airflow limitation and hyperinflation [24].  
Clinically these pathological and pathophysiological changes manifest as exertional dyspnoea, 
reduced exercise tolerance, the development of hypoxemia and hypercapnia. Mucus 
hypersecretion with chronic productive cough is present in patients with chronic bronchitis 
without airflow limitation as well as a substantial number of COPD patients who have chronic 
bronchitis phenotype, and is caused by the increased number of goblet cells and hypertrophy 
of the submucosal glands in the airways as a result of chronic irritation by the noxious agents, 
additionally stimulated by several inflammatory mediators [16].  
Interestingly, lung inflammation with its deleterious consequences persists even after smoking 
cessation, possibly through the involvement of autoantigens and lung microbiome [25]. The 
intensity of lung inflammation is further enhanced during COPD exacerbations triggered by 
respiratory infections and environmental factors, leading to reduced expiratory flow, 
increased hyperinflation, and worsening of respiratory symptoms [26]. Furthermore, 
pulmonary hypertension may develop late in the course of COPD as a result of hypoxic 
vasoconstriction, structural changes of the small pulmonary arteries, as well as the loss of the 
pulmonary capillary bed in emphysema, and may additionally worsen respiratory symptoms 
[27]. 
 
1.1.3.  Symptoms 
Chronic and progressive dyspnoea is the most common symptom of COPD, and a major 
cause of a disability [28]. Patients with severe and very severe COPD may experience 
dyspnoea even at rest or on minimal exertion. Dyspnoea is sometimes accompanied by 
wheezing and chest tightness.  
Chronic cough is often the first symptom of COPD, and may be productive or unproductive. 
Regular production of sputum for three or more months in two consecutive years in the 
absence of any other condition that may explain it is the seminal definition of chronic 
bronchitis, which may precede the development of airflow limitation [29]. Patients producing 
large volume of sputum may have underlying bronchiectasis, and those with persistently 
purulent sputum, even when clinically stable, may have chronic bronchial infection [30].  
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In advanced stages of COPD additional extrapulmonary manifestations of the disease can be 
expected including fatigue, weight loss, skeletal muscle wasting and dysfunction, symptoms 
of depression and anxiety [31, 32]. Cardiovascular complication of COPD is cor pulmonale 
that may lead to right-sided heart failure manifesting with hepatomegaly, peripheral oedema 
and ascites. 
 
1.1.4. Diagnosis and severity assessment 
1.1.4.1. Spirometric criteria 
COPD should be considered and post-bronchodilator spirometry should be performed in any 
patient who has dyspnoea, chronic cough or sputum production, and/or a history of exposure 
to risk factors [5]. While the screening spirometry in the general population is not 
recommended, performing spirometry in individuals with chronic respiratory symptoms 
and/or risk factors is indicated [5].  
Spirometry should be performed after the administration of an adequate dose of a short-acting 
inhaled bronchodilator (10-15 minutes after inhalation of 400 mcg of salbutamol or 30-45 
minutes after 160 mcg of ipratropium), and the measured parameters forced expiratory 
volume in one second (FEV1) and forced vital capacity (FVC) should be compared with the 
predicted values for height, age, sex, and race [33]. A post-bronchodilator ratio of FEV1/FVC 
< 0.70 confirms the presence of persistent airflow limitation, and is required to establish the 
diagnosis of COPD in a person with symptoms consistent with COPD and/or risk factors [5]. 
The classification of the severity of airflow limitation according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) is presented in Table 1 [5].  
Besides the presence and severity of the spirometric abnormalities, COPD assessment should 
consider patient’s symptoms, exacerbation history and future risk, and the presence of 
comorbidities [5].  
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Table 1. Classification of airflow limitation severity in COPD based on post-bronchodilator 
spirometry with FEV1/FVC < 0.70 [5]. 
GOLD 1 Mild FEV1 ≥ 80% predicted 
GOLD 2 Moderate 50% ≤ FEV1 < 80% predicted 
GOLD 3 Severe 30% ≤ FEV1 < 50% predicted 
GOLD 4 Very severe FEV1 < 30% predicted 
Abbreviations: COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease; FEV1: forced expiratory volume in one second; FVC: forced vital capacity. 
 
1.1.4.2. Assessment of symptoms severity  
Breathlessness is a very common symptom in patients with COPD, and together with airflow 
limitation is a predictor of mortality [34]. A simple, useful, and widely used measure of 
breathlessness is the modified Medical Research Council (mMRC) dyspnoea scale (grades 0-
4) [35, 36], which is depicted in Table 2. 
Table 2. Modified Medical Research Council (mMRC) dyspnoea scale [35]. 
mMRC grade 0 I only get breathless with strenuous exercise. 
mMRC grade 1 
I get short of breath when hurrying on the level or walking up a slight 
hill. 
mMRC grade 2 
I walk slower than people of the same age on the level because of 
breathlessness, or I have to stop for breath when walking at my own 
pace on the level. 
mMRC grade 3 
I stop for breath after walking about 100 meters or after a few minutes 
on the level. 
mMRC grade 4 
I am too breathless to leave the house or I am breathless when dressing 
or undressing. 
 
However, breathlessness is only one of the symptoms in COPD, which is a far more complex 
disease with respiratory and extrapulmonary manifestations. Due to the need for a more 
complete assessment of respiratory symptoms in COPD and their impact on activities of daily 
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living several comprehensive, disease-specific health status questionnaires were developed, 
one of them being the COPD Assessment Test (CATTM) (COPD Assessment Test and the 
CAT logo are trademarks of the GlaxoSmithKline group of companies). This is an 8-item 
measure of health status impairment in COPD with a score that ranges from 0-40 (Figure 1). 
The CATTM has been extensively used as a research method, but it is also suitable for the 
assessment of symptom burden in COPD patients in everyday clinical practice [37]. 
 
 
Figure 1. COPD Assessment Test (CATTM) [37]. 
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1.1.4.3. COPD exacerbations - assessment of risk 
COPD exacerbations are very heterogeneous events in terms of aetiology and clinical 
presentation. The European Respiratory Society (ERS) and the American Thoracic Society 
(ATS) task force defined COPD exacerbation as an increase in patient’s baseline dyspnoea, 
cough, and/or sputum production that usually requires a change in therapy [38]. Another 
proposed definition of COPD exacerbation is sustained worsening of the patient's condition 
from the stable state and beyond normal day-to-day variations that is acute in onset and may 
warrant additional treatment in a patient with underlying COPD [39].  
Published data suggest that approximately 70% of exacerbations are caused by respiratory 
infections, namely infections with aerobic bacteria (40–60%), respiratory viruses (about 
30%), and atypical bacteria (5–10%) [40, 41]. Polymicrobial aetiology was demonstrated in 
as much as 33% of exacerbations, being particularly important in the most severe cases [26]. 
Environmental factors, including low temperature and air pollution are considered causative 
for approximately 10% of exacerbations, depending on season and geographical settings [42]. 
Multifactor aetiology is not uncommon, e.g. a combination of infective and environmental 
factors or already mentioned polymicrobial infections [26]. Furthermore, noncompliance with 
respiratory medication and/or abrupt withdrawal of therapy is responsible for a certain 
proportion of exacerbations [43]. However, in some cases the aetiology remains unknown.  
When referring to a severity of COPD exacerbations, the most popular classification is based 
on healthcare utilisation. According to that classification “mild” exacerbations are self-
managed by the patient at home by increasing the usual COPD medication (short acting 
bronchodilators and/or inhaled corticosteroids [ICS]), “moderate” exacerbations are treated 
with antibiotics and/or oral corticosteroids in the outpatients settings, while “severe” ones 
require hospitalisation or emergency room visit [44]. 
Exacerbations have a negative impact on patient’s health-related quality of life and prognosis, 
they accelerate lung function decline, and severe exacerbations also bring significant 
mortality risk [45, 46]. Therefore it is important to assess the risk of future exacerbations in 
order to reduce it with an appropriate treatment strategy. 
Exacerbations become more frequent and more severe as COPD progresses and FEV1 
declines, but regardless of the COPD severity the best predictor of future exacerbations is a 
history of previous exacerbations [47]. Frequent exacerbator phenotype is usually defined by 
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≥ 2 exacerbations per year, and the main predictor of frequent exacerbator status in the 
following year among all grades of COPD severity is a history of frequent exacerbations in 
the previous year [48].  
Recent studies suggest that a baseline blood eosinophil count may serve as a marker of 
exacerbation risk in COPD patients with a history of moderate/severe exacerbations, and may 
predict the usefulness of ICS in addition to bronchodilators in reducing the exacerbation rate 
[49]. Although the results of a post-hoc analysis of some clinical trials have suggested the 
beneficial effect of ICS therapy in patients with blood eosinophil level ≥ 2% [49], a cut-off 
threshold for blood eosinophils in predicting future exacerbations risk is still to be 
determined.  
 
1.1.4.4. Additional investigations 
In the clinical assessment of a patient with COPD several additional investigations are 
frequently performed, although they are not necessary to establish a diagnosis of COPD. 
Chest radiograph (colloquially called a chest X-ray) may demonstrate some radiological 
changes associated with COPD and resulting lung hyperinflation (e.g. hyperlucency of the 
lungs, flattening of the diaphragm, increased retrosternal airspace and intercostal spaces), but 
its greatest value is in establishing the presence of other pulmonary, pleural, cardiac and 
skeletal diseases.  
Computed tomography (CT) of the chest is not routinely recommended in the management 
of COPD, but it may be useful in the differential diagnosis, when concomitant pathology is 
suspected (e.g. bronchiectasis, lung cancer, combined pulmonary fibrosis and emphysema), as 
well as in the evaluation of the distribution of emphysema when lung volume reduction 
procedures are considered [50].  
Body plethysmography with lung volumes measurement is a preferred method for the 
assessment of lung hyperinflation, which commonly accompanies expiratory airflow 
limitation in patients with COPD contributing to the severity of dyspnoea. Lung 
hyperinflation is characterised by the increase in end-expiratory lung volume, residual volume 
(RV), total lung capacity (TLC), and/or ratio of residual volume to total lung capacity 
(RV/TLC), and the values >120% of the predicted are considered clinically important, 
although these ‘‘cut-offs’’ remain arbitrary [51]. 
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Diffusing capacity of the lung for carbon monoxide (DLCO) is expected to be decreased in 
patients with emphysema where a gas-exchanging surface of the lung is reduced. 
Measurement of DLCO may be particularly useful in patients with breathlessness that seems 
out of proportion to the degree of airflow limitation [5]. 
In patients with clinical signs suggestive of respiratory failure pulse oxymetry should be used 
to measure peripheral capillary oxygen saturation (SpO2). In case of a resting stable SpO2 ≤ 
92% arterial blood gases sampling is required in order to assess eligibility for long-term 
oxygen therapy (LTOT) [52]. Arterial blood gases assessment is also indicated in hospitalised 
patients with severe COPD exacerbations for oxygen titration during supplemental oxygen 
therapy, as well as in the evaluation of a need for mechanical ventilation.   
Exertional dyspnoea is a common symptom in COPD that usually leads to the reduction in 
exercise capacity and physical activity. Since the impairment in physical performance has 
been recognised as a negative prognostic factor in COPD [53], exercise testing and objective 
measurement of physical activity may be useful in a comprehensive assessment of COPD 
severity. However, these are still underperformed in everyday clinical practice because their 
determination is time consuming, and remains largely reserved for research purposes. The 
exceptions are walking tests, mainly incremental shuttle walk test and 6-minute walk test 
(6MWT), which are also in clinical use mostly to evaluate the effectiveness of pulmonary 
rehabilitation. Different methods of assessing physical performance will be discussed in more 
detail in section 1.3. 
BODE index is a multidimensional 10-point scale that is used to predict long-term outcomes 
in COPD, in particular the risk of death [34]. In the calculation of BODE index four factors 
are evaluated: body mass index (BMI) (B); airflow obstruction (O), evaluated by the FEV1; 
severity of dyspnoea (D), assessed by the mMRC dyspnoea scale; and exercise capacity (E), 
measured by the 6-minute walk distance (6MWD). 
 
1.1.5. Classification of COPD 
The most widely used classification of COPD is the one given by the GOLD [54], which 
takes into consideration patient’s symptoms based on the mMRC dyspnoea scale (Table 2) 
[35] and/or the CATTM score (Figure 1) [37], severity of airflow limitation assessed by the 
spirometry (Table 1), and the risk of exacerbations based on previous exacerbation history. 
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Using these parameters patients are classified into one of the four categories – A, B, C or D 
(Figure 2), which determines a severity of the diseases, impact on patient’s health status, the 
risk of future events (exacerbations, hospitalisations, deaths) and serves as a guide in a 
therapy [54].  
 
 
 
  4 
  
         GOLD classification   3 
         of airflow limitation      
 
C 
 
D 
 
Exacerbation history 
≥ 2 or 
≥ 1 leading to hospital 
admission 
      
2 
 
1 
 
A 
 
B 
 
0 or 1 (not leading to 
hospital admission) 
 mMRC 0-1 
CAT < 10 
mMRC ≥ 2 
CAT ≥ 10 
 
Patient 
category 
Characteristics 
Spirometric 
classification 
Exacerbations 
per year 
CAT mMRC 
A Low risk, less symptoms GOLD 1-2 0-1 < 10 0-1 
B Low risk, more symptoms GOLD 1-2 0-1 ≥ 10 ≥ 2 
C High risk, less symptoms GOLD 3-4 ≥ 2 / ≥ 1 hosp. < 10 0-1 
D High risk, more symptoms GOLD 3-4 ≥ 2 / ≥ 1 hosp. ≥ 10 ≥ 2 
 
Figure 2. Classification of COPD according to the GOLD guidelines 2011-2016 [54].  
Abbreviations: CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary 
disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; hosp: hospitalised 
exacerbation; mMRC: modified Medical Research Council dyspnoea scale.  
 
The novelty of the GOLD 2017 in comparison to the GOLD 2011-2016 is that the ABCD 
categorisation is now determined only by the symptoms severity and exacerbation history, 
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while the degree of airflow limitation (spirometric grade 1 to 4) should be presented 
separately (e.g. GOLD grade 3, group D) (Figure 3) [5]. According to the GOLD 2017 
spirometry is no longer needed neither for the classification of COPD patients, nor for the 
initial therapeutic strategy; however, its role in the diagnosis, prognosis and follow-up is still 
irreplaceable [5]. 
 
Figure 3. Classification of COPD according to the GOLD guidelines 2017 [5]. 
Abbreviations: CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary 
disease; FEV1: forced expiratory volume in one second; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease; mMRC: modified Medical Research Council dyspnoea scale. 
 
However, it is now widely recognised that COPD is a very complex disease with a significant 
heterogeneity in clinical presentation and disease progression, and the term “phenotype” has 
recently become more common when referring to different clinical forms of COPD [55]. A 
group of international experts has defined COPD phenotypes as “those attributes of the 
disease that either alone or combined describe the differences between individuals with 
COPD regarding parameters that have clinical significance (symptoms, exacerbations, 
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response to therapy, progression rate of the disease, or death)” [55]. Established on the 
premise that the phenotypes enable the classification of patients into distinct prognostic and 
therapeutic subgroups, in recent years some national respiratory societies, e.g. Spanish and 
Czech respiratory societies, have developed guidelines for the diagnosis and treatment of 
COPD based on phenotypes [56, 57].  
Spanish guidelines propose four distinct phenotypes: (A) non-exacerbator, with emphysema 
or chronic bronchitis; (B) mixed COPD-asthma; (C) exacerbator with emphysema; (D) 
exacerbator with chronic bronchitis (Figure 4) [56].  
 
Figure 4. COPD clinical phenotypes according to the Spanish guidelines [56]. 
 
 
The emphysema phenotype includes COPD patients with clinical / radiological / functional 
diagnosis of emphysema who present dyspnoea and exercise intolerance as predominant 
symptoms [56]. Furthermore, chronic bronchitis is defined as the presence of productive 
cough or expectoration for more than three months a year during more than two consecutive 
years [58]. The mixed COPD-asthma phenotype is characterised by the symptoms of 
increased variability of airflow accompanied by the incompletely reversible airflow 
obstruction and increased bronchodilator responsiveness [59]. For the clinical identification of 
mixed COPD-asthma phenotype 2 major diagnostic criteria or 1 major and 2 minor criteria 
should be met - Table 3 [60]. The exacerbator phenotype includes COPD patients who appear 
with two or more moderate or severe exacerbations a year requiring treatment with systemic 
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corticosteroids and/or antibiotics, and this phenotype may coexist with the three previous 
phenotypes [56].  
 
 
Table 3. Major and minor criteria for establishing the diagnosis of mixed COPD-asthma 
phenotype in COPD [60]. 
Major criteria 
  Very positive bronchodilator test (increase in FEV1 >15% and >400 ml) 
  Eosinophilia in sputum 
  Personal history of asthma 
Minor criteria 
  High levels of total IgE 
  Personal history of atopy 
  Positive bronchodilator test on at least two occasions (increase of FEV1 >12% and >200 ml) 
Abbreviations: FEV1: forced expiratory volume in one second; IgE: immunoglobulin E. 
 
 
Similarly to Spanish guidelines, Czech COPD guidelines distinguish bronchitic phenotype, 
emphysematic phenotype, overlap COPD + asthma, and frequent-exacerbation phenotype, but 
apart from them they propose two additional phenotypes, namely pulmonary cachexia 
phenotype and overlap COPD + bronchiectasis [57]. Pulmonary cachexia phenotype is 
characterised by the decrease in body weight (BMI <21 kg/m2), and particularly in fat-free 
mass (FFM) (fat-free mass index [FFMI] <16 kg/m2 in men, <15 kg/m2 in women) [57]. 
Overlap COPD + bronchiectasis phenotype includes COPD patients with radiological 
confirmation of bronchiectasis by the high-resolution CT scan, and clinically they are 
recognised by the chronic purulent expectoration, lower or no smoking burden, younger age, 
history of prolonged/recurrent respiratory infections and episodic haemoptysis [57]. 
Occasionally different phenotypes may occur simultaneously in an individual patient (e.g. 
emphysematic phenotype and cachexia, or bronchitic phenotype with frequent exacerbations) 
[57]. 
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1.1.6. Treatment of COPD 
Treatment of COPD includes different pharmacologic and non-pharmacologic therapeutic 
interventions with the main objectives to reduce symptoms, prevent exacerbations, delay the 
natural progression of the disease, and to improve the health-related quality of life.  
Since smoking has a deleterious effect in the development and progression of COPD, all 
patients who continue to smoke should be strongly encouraged to quit, and if needed, 
pharmacotherapy for smoking cessation may be included (e.g. nicotine replacement products, 
varenicline, bupropion) [61].  
Influenza and pneumococcal vaccinations are recommended for all COPD patients as a part 
of general non-pharmacologic measures [5]. 
Inhaled bronchodilators are the mainstay of the pharmacologic treatment of COPD. By 
combining bronchodilators of different classes the degree of bronchodilation may increase 
with a lower risk of side-effects compared to increasing the dose of a single bronchodilator 
[62]. Short-acting inhaled bronchodilators, namely short-acting beta2-agonists, SABA (e.g. 
salbutamol) and short-acting muscarinic antagonists, SAMA (e.g. ipratropium) are used as 
symptom-relieving treatment usually on an as-needed basis, and as monotherapy they are 
sufficient only in oligosymptomatic patients with mild COPD [5]. Patients with moderate, 
severe and very severe COPD require prolonged bronhchodilation, which can be achieved 
with long-acting muscarinic antagonists, LAMA (e.g. tiotropium, umeclidinium, aclidinium, 
glycopyrronium) and/or long-acting beta2-agonists, LABA (e.g. formoterol, salmeterol, 
indacaterol, olodaterol) [63]. When used on a regular basis long-acting inhaled 
bronchodilators exhibit many clinical benefits – they improve lung function (increase FEV1), 
reduce resting and dynamic lung hyperinflation, alleviate dyspnoea, reduce exacerbation rate, 
and improve exercise tolerance, health status and quality of life [64]. However, so far there is 
no evidence that these drugs affect lung function decline, disease progression and mortality. 
Corticosteroids are efficient anti-inflammatory drugs that have been used in COPD for a 
long time, but in recent years their indications have become more restricted due to potential 
adverse effects and the evidence of benefit only in a selected group of patients with distinct 
clinical phenotypes [65]. The current guidelines recommend the treatment with ICS in 
association with LABA for COPD patients with a history of frequent exacerbations despite 
appropriate treatment with long-acting bronchodilators, and for patients with features of both 
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asthma and COPD, i.e. athma-COPD overlap syndrome [5, 56, 57]. It has been suggested that 
the presence of sputum and blood eosinophilia may serve as a predictor of response to ICS in 
COPD [49]. ICS in a combination with LABA reduce exacerbation rate, and improve lung 
function and health status in selected COPD patients, though there is no evidence of survival 
benefit or effect on long-term FEV1 decline [65, 66].  
Systemic corticosteroids are not recommended in the treatment of stable COPD; however, a 
short course (≤ 14 days) of systemic corticosteroids is indicated in COPD exacerbations, 
preferably orally administered rather than intravenously even in hospitalised patients [67].  
There is evidence to support treatment of COPD exacerbations with systemic corticosteroids 
in reducing the risk of early relapse, shortening recovery time and length of hospital stay, and 
improving lung function and symptoms [68]. 
Methylxanthines (e.g. theophylline, aminophylline) are non-selective phosphodiesterase 
inhibitors with a weak bronchodilator and anti-inflammatory activity, and some additional 
effects of which clinical relevance is still not clear, such as a potential to increase respiratory 
muscle activity and reverse corticosteroid resistance [69, 70]. Theophylline is given orally as 
slow-release preparations in stable COPD, and aminophylline is given intravenously in 
exacerbations, but their use is constantly declining because of a relatively small therapeutic 
effect, significant interactions with commonly used medications and frequent side effects, 
especially in elderly persons [69].   
Roflumilast, a selective phosphodiesterase-4 inhibitor is a relatively new drug with a variety 
of anti-inflammatory effects, and besides some improvement in lung function its main clinical 
benefit is a reduction of moderate and severe exacerbations [71]. As part of a combination 
regimen with long-acting bronchodilators, roflumilast is indicated in the treatment of patients 
with severe to very severe COPD (FEV1 <50% predicted) associated with chronic bronchitis 
and a history of exacerbations [71]. 
Regarding antibiotics there is evidence supporting their use in COPD exacerbations with 
clinical signs of a bacterial infection, e.g. increased sputum purulence [72], as well as in 
severe exacerbations requiring invasive or noninvasive mechanical ventilation [73]. Antibiotic 
therapy in COPD exacerbations reduces the risk of short-term mortality and treatment failure, 
and increases the time between exacerbations [74]. The choice of the antibiotic should be 
based upon local bacterial sensitivity patterns [67]. 
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Although there is still some controversy in the preventive antibiotic use in stable COPD, there 
is evidence of the effectiveness of prolonged intermittent use of some antibiotics (e.g. 
azithromycin, moxifloxacin) in decreasing the exacerbation rate in patients with an increased 
risk of exacerbations [75, 76]. However, due to potential side-effects and the development of 
bacterial resistance the candidates for the preventive antibiotic therapy should be strictly 
selected among patients with severe COPD and signs of chronic bronchial infection (e.g. 
chronic bronchitis phenotype with permanently purulent sputum, carriers of bronchiectasis) 
who experience recurrent infective exacerbations despite adequate therapy [56]. 
Mucolytic agents (e.g. N-acetylcysteine, carbocysteine) are recommended as additional 
therapy in patients with chronic bronchitis phenotype and frequent exacerbations [5, 56]. 
There is evidence that the treatment with mucolytics may produce a small reduction in the 
frequency of exacerbations and a small effect on the overall quality of life, especially in 
patients not receiving ICS [77]. 
Candidates for alpha-1 antitrypsin augmentation therapy are patients with severe 
hereditary alpha-1 antitrypsin deficiency (serum levels of alpha-1 antitrypsin <11.0 μM), 
established emphysema, postbronchodilator FEV1 between 30-65% predicted or if they 
experience a rapid decline in lung function (ΔFEV1 >120 ml/year) [78]. 
Pharmacologic treatment algorithms suggested by the GOLD 2017 guidelines are presented in 
Figure 5 [5]. 
Pulmonary rehabilitation has a central place in the non-pharmacologic treatment of COPD, 
and among others includes structured and supervised exercise training, education, and 
behavioural change, all designed to improve the physical and psychological condition of a 
patient [79]. It is indicated for patients who have decreased exercise tolerance, exertional 
dyspnoea or fatigue, and/or impairment of activities of daily living [80]. Pulmonary 
rehabilitation should be considered (a) at diagnosis, (b) at discharge following hospitalisation 
for an exacerbation, and (c) when symptoms are progressively deteriorating despite optimal 
pharmacologic therapy [5]. The evidence for improvement in exercise endurance, dyspnoea, 
functional capacity, and quality of life is stronger for pulmonary rehabilitation than for almost 
any other therapy in COPD [80, 81]. Despite previous evidence that pulmonary rehabilitation 
after an exacerbation may also reduce readmissions and mortality, more recent studies have 
failed to show the benefit on these outcomes [81].  
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Figure 5. Pharmacologic treatment algorithms for A-D GOLD categories of COPD [5].  
Abbreviations: FEV1: forced expiratory volume in one second; ICS: inhaled corticosteroids; 
LABA: long-acting beta2-agonists; LAMA: long-acting muscarinic antagonists. 
 
Nutritional supplementation is indicated in malnourished patients with COPD based on the 
evidence of positive effects on weight gain, FFM, fat-mass (FM), respiratory muscle strength, 
exercise tolerance and the health-related quality of life [82].   
In patients with severe chronic respiratory failure LTOT improves survival [83]. LTOT is 
recommended for stable COPD patients with partial pressure of oxygen in arterial blood (pO2) 
≤ 7.3 kPa (55 mmHg) or arterial oxygen saturation (SatO2) ≤ 88% confirmed twice over a 
three week period in resting condition [5]. For COPD patients with pulmonary hypertension, 
peripheral oedema suggesting congestive cardiac failure, or polycythemia (haematocrit > 
55%) LTOT is indicated if pO2 ≤ 8.0 kPa (60 mmHg) [5]. 
Non-invasive ventilation (NIV) in the form of non-invasive positive pressure ventilation is 
the standard of care for patients hospitalised for severe COPD exacerbations with respiratory 
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failure [5]. It has been proven that in these patients NIV improves oxygenation and 
respiratory acidosis, reduces the need for intubation and invasive ventilation, decreases length 
of hospital stay, and reduces in-hospital complications (e.g. ventilator associated pneumonia) 
and mortality [84]. However, the evidence of survival benefit and lower readmission rate 
when using NIV at home is not as conclusive, but it may be considered in selected patients 
with very severe COPD and persistent daytime hypercapnia (i.e. partial pressure of carbon-
dioxide in arterial blood (pCO2) ≥ 52 mmHg) after hospitalisation [5, 85]. On the other hand, 
in patients with both COPD and obstructive sleep apnoea there is strong evidence in favour of 
using continuous positive airway pressure (CPAP) as an intervention that improves survival 
and reduces the risk of hospitalisation [86]. 
Interventional bronchoscopy and surgery may be considered in selected COPD patients. In 
patients with advanced emphysema and significant hyperinflation lung volume reduction may 
be achieved by the surgical methods (e.g. lung volume reduction surgery, bullectomy) or 
bronchoscopic methods (e.g. placement of endobronchial valves or lung coils) [87, 88]. A 
selection of a method depends on several factors including lung function, extent and pattern 
of emphysema, presence of interlobar collateral ventilation (i.e. fissure integrity), availability 
of a certain method, and patient and providers preferences [5].  
Lung transplantation remains an option for patients with end-stage COPD without 
significant comorbid conditions. Criteria for the referral for lung transplantation include 
COPD with progressive disease course despite maximal treatment, not a candidate for 
endoscopic or surgical lung volume reduction, BODE index of 5 to 6, pCO2 > 6.6 kPa (50 
mmHg) and/or pO2 < 8 kPa (60 mmHg), and FEV1 < 25% predicted [89]. Criteria for listing 
include at least one of the following: BODE index ≥ 7, FEV1 < 15-20% predicted, ≥ 3 severe 
exacerbations during the preceding year, one severe exacerbation with acute hypercapnic 
respiratory failure, moderate to severe pulmonary hypertension [89]. 
 
1.1.7. Comorbidities and extrapulmonary manifestations of COPD 
Patients with COPD often suffer from other chronic medical conditions. Although respiratory 
symptoms dominate in the clinical presentation of COPD, and maximum efforts are directed 
toward their reduction, concomitant diseases may aggravate clinical manifestations of COPD 
and worsen its prognosis. Comorbidities that are most frequently reported include ischaemic 
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heart disease, heart failure, systemic and pulmonary hypertension, metabolic syndrome, 
diabetes mellitus, dyslipidaemia, osteoporosis, obstructive sleep apnoea, lung cancer, 
anaemia, weight loss, skeletal muscle wasting and/or dysfunction, and psychological 
disorders such as depression and anxiety [90, 91]. In a study by Mapel et al. [92] patients with 
COPD had an average of 3.7 comorbidities compared to 1.8 for the control subjects, and only 
6% of COPD patients did not have any other chronic medical condition. COPD and many of 
reported comorbidities often share the same risk factors, the most important being tobacco 
smoking and ageing. However, such a high incidence of different comorbidities in COPD 
cannot be attributed only to the common predisposing factors, and there is increasing 
evidence that chronic low-grade systemic inflammation, chronic hypoxia, and sedentary 
lifestyle play an important role in the pathogenesis of comorbidities in patients with COPD 
[93]. Inflammatory response in COPD is not limited only to the lungs, but there is also a 
certain level of systemic inflammation, both during exacerbations and in stable periods, which 
in a significant number of cases may be attributed to the chronic bronchial infection [94]. 
Consequently, it has been suggested that a chronic systemic inflammation may be the 
common pathway linking COPD and comorbidities, and that in fact many comorbidities may 
actually be considered systemic/extrapulmonary manifestations of COPD [95].  
Furthermore, some COPD medications may contribute to certain concomitant diseases, e.g. 
ICS increase the risk of pneumonia, and when used in high doses may predispose to cataracts 
and osteoporosis, bronchodilators may contribute to tachyarrhythmias, inhaled 
anticholinergics may predispose to glaucoma and urinary retention, while systemic 
corticosteroids affect different tissues and organs increasing the risk of osteoporosis, diabetes, 
hypertension, muscle dysfunction, and adrenal insufficiency [90].  
The presence of comorbidities often worsen clinical presentation of COPD with a negative 
impact in terms of quality of life, exacerbations, hospitalisations and mortality [91]. 
Therefore, as part of the comprehensive care of patients with COPD an additional effort 
should be made for an early diagnose and appropriate treatment of each concomitant medical 
condition, which generally does not differ from the management in subjects without COPD.  
 
1.2.  Evaluation of nutritional status and body composition in COPD 
One of the systemic manifestations of COPD is a change in the nutritional status, namely 
body weight and body composition alterations, which reflect a complex interaction between 
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the effects of genetics, lifestyle and disease on muscle, bone and fat tissue [96]. Malnutrition 
arises from a combination of inflammation and a disturbed nutrient balance involving the 
intake of energy (calories), proteins, carbohydrates, fats, vitamins, minerals and other 
nutrients required to maintain the normal structure of human organs and their functioning [97, 
98]. By definition the malnourished state includes both undernutrition (lack of nutrients) and 
overnutrition (excess of nutrients), resulting with health problems in both situations [97, 98].  
However, the narrower sense of the term malnutrition refers to undernutrition, and in clinical 
practice it is more often used in that context.  
Back in 1968, Filley et al. [99] already distinguished two contrasting types of COPD patients, 
i.e. the emphysematous type (“pink puffer”) and the bronchial type (“blue bloater”) that 
besides the differences in the respiratory and cardiovascular features also exhibit distinct body 
habitus. More recent scientific research on this topic has shown that body weight and body 
composition variables represent a continuous spectrum, and that nutritional abnormalities in 
COPD patients are predictors of outcome independent of lung function impairment [96]. 
The BMI, calculated as weight/height squared (kg/m2) is the most commonly used 
anthropometric parameter in the assessment of nutritional status in adults. The WHO suggests 
the following BMI classification: underweight (<18.5 kg/m2), normal weight (≥18.5, <25 
kg/m2), overweight (≥25, <30 kg/m2), and obese (≥30 kg/m2) [100]. However, studies on 
COPD frequently use a BMI <20 or <21 kg/m2 to define underweight, since a higher mortality 
was observed in COPD patients with BMI below these values [101, 102]. The cut-off BMI 
<21 kg/m2 for underweight patients with COPD is also recommended by the ATS/ERS [103]. 
Body composition is more informative than BMI, but it is highly influenced by many 
biological factors, such as age, gender, genetics, ethnicity, dietary intake, physical activity, 
and the presence of disease [104]. Information on human body composition can be collected 
at five distinct levels of increasing complexity: atomic, molecular, cellular, tissue, and whole-
body level (Figure 6) [105]. At the atomic level six chemical elements (oxygen, hydrogen, 
carbon, nitrogen, calcium, and phosphorus) account for over 98% of the body mass [105]. At 
the molecular level the human body is composed of water, lipids, proteins, glycogen, and 
minerals, while at the cellular level it can be divided into cell mass, extracellular fluids, and 
extracellular solids [105]. Furthermore, four main body components at the tissue level are 
skeletal muscles, bones, adipose tissue, and internal organs [105]. Nevertheless, in clinical 
practice the most widely used approach to estimate body composition is a two-compartment 
model of body composition, in which the body is divided into FM and FFM [104]. On a tissue 
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level the FFM comprises skeletal muscles, bones and internal organs, while on a molecular 
level it consists of water (approximately 73%), proteins (20%), minerals (7%), and a small 
amount of carbohydrates (mainly glycogen and glucose) [104, 106]. The lean body mass and 
the FFM are usually used as synonyms, while the lean soft tissue mass (LM) represents bone-
free FFM. On the other hand, the main component of the FM on a tissue level is adipose 
tissue with reserves of a body fat, which chemically mainly consists of triglycerides. Adipose 
tissue can be classified as two main types: subcutaneous (adipose tissue directly underneath 
the skin), and internal adipose tissue, which is further subdivided into visceral (adipose tissue 
surrounding the internal organs), and nonvisceral internal adipose tissue (e.g. adipose tissue in 
bone marrow, interstitial adipose tissue between muscle fibres, and retro-orbital, paravertebral 
and  intra-articular adipose tissue) [106]. 
 
 
Figure 6. Five-level body composition model. Adapted from references 104 and 105. 
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In the assessment of nutritional status and body composition different methods may be 
applied depending on the population studied and the purpose of the investigation:  
1) Questionnaires [107] – ESPEN, the European Society for Clinical Nutrition and 
Metabolism, recommends several questionnaires as screening tools to detect undernourished 
patients: MUST (Malnutrition Universal Screening Tool), NRS-2002 (Nutritional Risk 
Screening), and MNA (Mini Nutritional Assessment). Methods to assess dietary intake 
include food frequency questionnaires, 1-7 day food records, and 24-hour dietary recalls. 
2) Anthropometry [100, 104] – includes direct measurements of different anthropometric 
variables (e.g. height, weight, circumferences of the waist, hips, upper arm, forearm, thigh 
and calf, skinfold thickness at specific anatomic locations) followed by the calculation of 
more complex anthropometric parameters using specific equations. Anthropometric 
instruments are portable and inexpensive, procedures are non-invasive and minimal training is 
required. 
3) Bioelectric impedance analysis (BIA) [104, 108] – it is one of the most frequently used 
methods for estimating body composition due to its relatively low cost, ease of use, 
portability, and safety (not recommended for participants with a pacemaker). It measures the 
impedance or resistance to a small alternating electrical current as it travels through the 
body’s water pool. Skeletal muscles have both a large volume and low resistance owing to the 
high electrolyte content, while adipose tissue and bones have poor conductance properties, 
and consequently most of the current in a whole-body BIA measure flows through skeletal 
muscles. An estimation of the total body water should allow calculation of the FFM based on 
the assumption that all the water in the body is in the FFM, and that 73% of the FFM is water. 
Moreover, FM can be determined by subtracting FFM from total body mass. The 
disadvantage of BIA is its reference-method dependence; that is, BIA resistance measures 
must be mathematically transformed into the body composition component of interest using 
prediction equations, which are population specific. Furthermore, BIA measures are 
dependent on hydration status, which reduces the reliability of this method in some clinical 
situations (e.g. recent food/fluids consumption, recent exercise, dehydration, congestive heart 
failure, renal insufficiency, diuretic therapy, dialysis). 
4) Dual energy X-ray absorptiometry (DEXA) [104, 108] – this method is more exact than 
BIA and enables determination of three components of the human body: bone mineral content 
(BMC) with bone mineral density (BMD), bone-free FFM (i.e. LM), and FM in addition to 
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their regional distribution. The basic physical principle behind DEXA is the measurement of 
the transmission of a low-photon (~40 keV) and a high-photon (~80 keV) X-ray through the 
body. The intensity of the X-ray is attenuated when passing through the body, but the level of 
attenuation differs for different tissues, which enables body composition estimation based on 
complex mathematical equations. This method is relatively quick (≤ 15 min for the whole-
body scan), non-invasive, precise, and reproducible. DEXA is considered the gold standard 
technique for the diagnosis of osteopenia and osteoporosis. Disadvantages include a small 
dose of radiation (equivalent to that received on a transcontinental flight or between 1 and 
10% of a chest radiograph), and a limitation by the subject’s weight and size (must fit into the 
scanning field). 
5) CT and magnetic resonance imaging (MRI) [104, 108] – these are the most accurate 
methods available for in vivo quantification of body composition at the tissue level. CT and 
MRI allow for the estimation of adipose tissue, skeletal muscle, and are the only methods 
available for the measurement of internal organs. Routine use of these imaging techniques is 
limited by access and cost, so they are now mostly used in body composition research. 
6) Isotope dilution techniques [108] – total body water can be measured by several isotope 
dilution techniques using water labelled with the isotope of oxygen (18O) or hydrogen (2H or 
3H). Assuming that the hydration of FFM is relatively constant in healthy subjects (i.e. total 
body water/FFM = 0.732), measurement of total body water allows for the evaluation of FFM 
and FM. This method is mainly used in body composition research. 
7) Laboratory assessment [109, 110] – includes identification of different nutrients and 
metabolites in biological specimens (e.g. blood, urine, saliva, hair, adipose tissue), which 
ideally reflect dietary exposures and nutritional status. Many nutritional biomarkers are 
available, however their clinical utility in the nutritional assessment may be limited due to 
numerous factors that affect the metabolism of each nutrient. Albumin, prealbumin, 
transferrin, and retinol-binding protein have been suggested as markers of protein status. 
Albumin is a serum protein synthesized by the liver, it is a negative acute phase reactant, 
which levels decrease during the acute phase response (e.g. inflammation, infection, 
metabolic stress, trauma, post-operative state), and besides that its serum concentration is 
affected by many other factors (e.g. hydration status, liver disease, nephrotic syndrome, burns 
and other protein losing states, pregnancy) [110, 111]. Because of its relatively large body 
pool size (more than 50% is located extravascularly), and a long half-life (14-20 days), serum 
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albumin levels do not reflect acute changes in protein intake, but it may be considered a 
marker of chronic nutritional status [110].  
Prealbumin is also a negative acute phase reactant, but its advantage over albumin is a 
shorter half-life (2-3 days) and a smaller body pool, so it is expected to respond more rapidly 
to changes in nutrient intake [110]. 
Transferrin is involved in iron transport, and its levels increase in iron deficiency, which 
limits its usefulness in protein status assessment [110].  
Retinol-binding protein forms retinol-circulating complex together with prealbumin and 
retinol, and as a marker of protein status generally has similar characteristics as prealbumin 
[110]. 
Since malnutrition may also affect the immune system, several immunological tests (e.g. total 
lymphocyte count, delayed cutaneous hypersensitivity testing) may be applied as a 
functional measure of nutritional status [98]. 
 
1.3.  Evaluation of physical performance in COPD 
Physical activity can be defined as any bodily movement produced by skeletal muscles that 
results in energy expenditure, and includes different kinds of activities, such as domestic, 
occupational and leisure-time activities [112]. Exercise is a subset of physical activity that is 
planned, structured, repetitive and purposeful with an objective to improve or maintain 
physical fitness and exercise capacity - the maximum amount of physical exertion that a 
person can sustain [112, 113]. Furthermore, activities of daily living are another subset of 
physical activity that includes a set of basic, everyday tasks required for personal self-care and 
independent living [114]. 
Patients with COPD are markedly less physically active compared with age-matched healthy 
individuals, which becomes more evident with increasing COPD severity [115, 116]. Reduced 
exercise capacity and low physical activity in COPD have been related to multiple negative 
outcomes including poor health-related quality of life, increased exacerbation risk, and higher 
mortality [117-120]. For this reason, it is important to assess physical performance, quantify 
physical activity, and to employ additional effort in their improvement. In the evaluation of 
physical performance different methods are used, depending on the clinical settings, purpose 
of the investigation, and availability of financial resources.  
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Cardiopulmonary exercise testing is incremental, symptom-limited exercise testing, which 
is performed on a cycle ergometer or a treadmill in a specially equipped laboratory, and 
includes measurement of different cardiovascular and respiratory parameters [121]. 
Cardiopulmonary exercise testing allows a valid and comprehensive assessment of 
cardiopulmonary function capability. 
The most commonly employed field walking tests are the 6MWT, incremental shuttle walk 
test, and endurance shuttle walk test, which are proven to be a valid and reliable measure of 
exercise capacity for people with chronic respiratory diseases [122].  
The 6MWT [122, 123] is a self-paced test of walking capacity in which subjects are asked to 
walk as far as possible in 6 minutes along a flat corridor between two cones spaced 30 metres 
apart. The test includes measurement of pulse and SpO2 by the continuous pulse oximetry, 
rating levels of baseline and post-test dyspnoea and fatigue according to the Borg scale, and 
most importantly recording of the total distance walked expressed in metres (i.e. 6-minute 
walk distance - 6MWD).  
The incremental shuttle walk test [122] is an externally paced maximal exercise test in 
which the speed of walking is controlled by a series of pre-recorded signals, and the total 
distance walked is recorded. The participant is required to walk between two cones spaced 10 
metres apart with gradual increase in the speed of walking until he cannot keep up with the set 
pace, or becomes too breathless or too tired to continue. 
The endurance shuttle walk test [122] is an adaptation of the incremental shuttle walk test 
designed to assess endurance exercise capacity. Subjects are asked to walk for as long as 
possible at a constant pace that is a predetermined percentage of maximum walking 
performance as assessed by the incremental shuttle walk test. The primary outcome of the 
endurance shuttle walk test is time (expressed in minutes and seconds), although it can also be 
expressed as distance completed.  
Several other simple field tests are available for a rapid assessment of physical performance, 
such as the gait speed test, timed chair stand test, and timed up and go test. 
Gait speed is easily measured and enables the assessment of walking functional mobility. 
There are different versions of gait speed test, which differ in a distance walked and whether 
the usual or maximum speed is measured. In the original 4-metre gait speed (4MGS) test 
[124] the participant walks 4 metre distance at his usual pace, and if needed he is allowed to 
use his normal walking aid (e.g. cane). Briefly, the 4 m distance is marked out on the floor 
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with tape, the participant is positioned with his toes just touching the start line, timing with 
the stopwatch starts when the participant begins to move and stops when his/her first foot 
completely crosses the 4-m line. The test is repeated without rest, and the faster of the two 
times is used to calculate 4MGS expressed in m/s. The 4MGS was proven to be a reliable and 
valid indicator of functional impairment in patients with COPD, and it correlates well with 
exercise capacity, dyspnoea and the health-related quality of life [124]. 
The timed chair stand test [125] was developed for the assessment of lower limb muscle 
strength in older people. There are several variants of this test – either to measure the time 
that a participant needs to rise 10 (original test), 1 or 5 times from a standard height chair (46 
cm) with arms folded across the chest, or to measure the number of stands from a chair in 30 
seconds (i.e. 30-second chair stand test) [126] or in a 1 minute period (i.e. sit-to-stand test) 
[127]. 
The timed up and go test [128] is a reliable and valid test for quantifying functional mobility 
of frail elderly people. The participant is observed and timed while he rises from an arm chair, 
walks 3 metres at normal pace, turns, walks back, and sits down again. Use of a walking aid is 
permitted in this test.  
Physical performance is directly related to a peripheral muscle mass, strength and endurance, 
which all often become impaired with the progression of COPD [129]. Muscle mass and its 
surrogate indicators, namely FFM and LM, can be quantified using one of the methods for 
body composition analysis (e.g. anthropometry, BIA, DEXA), as explained in the previous 
section. Additionally, in the assessment of regional limb muscle mass several other techniques 
are available, such as CT, MRI and ultrasonography, which have been used to assess 
quadriceps size in patients with COPD [129]. On the other hand, muscle function is evaluated 
by the measurement of muscle strength and/or endurance with different methodologies 
depending on whether muscle contraction is isometric or isokinetic, voluntary or involuntary 
(i.e. muscle contraction in response to an electrical or magnetic stimulation of a peripheral 
nerve) [129]. In the studies investigating muscle function in patients with COPD, isometric 
quadriceps maximal voluntary contraction strength, and the handgrip strength are most 
commonly measured [130, 131].  
Assessment of overall physical activity is complex, and on the one hand includes widely 
available, low-cost methods, such are questionnaires and pedometers, and on the other hand 
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more accurate, sophisticated and expensive methods, such are accelerometers and doubly 
labelled water method [132]. 
Physical activity questionnaires and diaries are inexpensive and easy to use research 
instruments that are commonly used in epidemiological studies and large clinical trials to 
evaluate the different aspects of physical activity [133]. Among 104 available questionnaires 
that measure physical activity in elderly and chronically ill populations, 15 were developed 
for use in patients with COPD [134]. The main limitation is their lack of accuracy due to 
recall bias [133]. 
Pedometers or step counters are small, lightweight, portable and relatively inexpensive 
devices that measure the number of steps that a person creates in a given period of time [132]. 
They are usually worn on the waist and designed to detect vertical movements of the hips 
while walking, although some newer models of pedometers in the form of bracelet detect arm 
swing during walking. With some additional information including the average step length, 
height and weight of the subject pedometers may also roughly estimate distance walked and 
energy expenditure [132]. Nevertheless, their main disadvantage is that they tend to be less 
accurate and generally underestimate activity in individuals with slower walking speed, which 
makes them impractical for use in patients with advanced COPD who usually walk very 
slowly [135]. Furthermore, pedometers are not able to detect other forms of physical activity 
such are cycling, swimming and static exercise, what might be an issue when assessing 
physical activity in patients in early stage of COPD who still do some recreational sport 
activities. 
Accelerometers or activity monitors are portable electronic devices worn on the body 
(usually on the waist, wrist, upper arm, or ankle) that measure quantity and intensity of bodily 
motion by detecting acceleration, and convert it to vector magnitude units (the vectorial sum 
of activity counts in different directions) [132, 135]. Accelerometers can detect movements 
along one axis (uni-axial accelerometers, which provide information similar to pedometers, 
but with the advantage of assessing acceleration in addition to simply detecting steps), two 
axes (bi-axial accelerometers) or three axes (tri-axial accelerometers) [132]. Some activity 
monitors have additional sensors for measuring other physiological functions (e.g. heart rate, 
skin temperature), which increases their accuracy in the estimation of daily physical activity 
and energy expenditure [132]. Reliability and validity of accelerometers, especially new ones 
with improved technology is generally high, which was also confirmed in several studies with 
COPD patients [135-137]. When measuring physical activity in daily life recommendation for 
    
 
28 
 
the number of assessment days is not straightforward and it depends on the population 
studied, but it is usually suggested that between 4 and 12 measurement days are needed to 
obtain accurate data [135]. 
Doubly labelled water method provides an indirect assessment of total energy expenditure 
by the body over a period of time [132]. The technique is based on the ingestion of water 
labelled with the hydrogen isotope 2H known as deuterium (i.e. 2H2O), and with the oxygen 
isotope 18O (i.e. H2
18O) in a known ratio [138]. The deuterium is eliminated through the urine, 
whereas the 18O is eliminated through the urine and CO2, and by measuring their elimination 
rates in the urine one can estimate the CO2 production, which further enables the calculation 
of energy expenditure [138]. Although this method is considered a “gold standard” for 
measuring the caloric cost of physical activity, its main drawback is that it actually does not 
allow separation of energy expenditure linked to physical activity and energy expenditure 
linked to basal metabolism and diet-induced metabolism, which needs to be taken into 
account when using this method in different study populations [132]. 
 
1.4.  Background for the presented research 
Respiratory symptomatology predominates in the clinical presentation of COPD, and for a 
long time it has been the main focus of diagnostic assessment and therapeutic efforts. 
However, extrapulmonary manifestations of COPD are increasingly being recognised as 
important determinants of disease severity and prognosis, and in the last two decades have 
become the subject of extensive scientific research [95]. Among common systemic 
manifestations of COPD are nutritional alterations and shifts in body composition, i.e. 
changes in the FFM, FM and BMC [96, 139]. Body weight loss and/or FFM depletion 
(defined as a FFMI <15 kg/m2 for women and <16 kg/m2 for men) are observed in 20-40% of 
COPD patients, with increasing prevalence in advanced stages of the disease, especially in 
women [140-142]. Different forms of nutritional depletion and body composition 
abnormalities have been described in COPD patients – cachexia (reduction in both body 
weight and FFM), semistarvation (reduction in body weight with normal FFM), and muscle 
atrophy (reduction in FFM with normal body weight) [143]. It is of clinical importance that 
skeletal muscle mass waste, reflected in the reduction of LM and FFM, together with low 
body weight have been recognised as predictors of increased disability and mortality in 
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COPD [142, 144]. Additionally, a low FFMI is a strong predictor of mortality even in the 
COPD population with a normal BMI [143]. 
Loss of skeletal muscle mass (i.e. sarcopenia) is closely linked to COPD-related limb muscle 
dysfunction, which besides muscle fibre atrophy includes different structural and functional 
alterations of peripheral muscle, such as a reduced muscle capillarisation, muscle fibre type 
shifting from type I to II, reduced mitochondrial density and function, decreased muscle 
oxidative/aerobic capacity, enhanced muscle protein turnover, low mechanical efficiency and 
high resting energy expenditure [129]. Peripheral skeletal muscle dysfunction, as most 
frequently evidenced by a reduction in quadriceps strength and endurance, is demonstrable in 
one-third of COPD patients (even in those with mild disease), and associated with many 
important clinical implications including exercise intolerance, reduced quality of life, and 
increased health care use and mortality [129, 130, 145]. Although all mechanisms underlying 
the development of peripheral muscle wasting and dysfunction are not yet known, some 
contributing factors have been identified: deconditioning due to physical inactivity, 
inflammation (chronic low-grade systemic inflammation with additional increase in the 
inflammatory response during exacerbations), hypoxia, hypercapnia with tissue acidosis, local 
and systemic oxidative stress, corticosteroid therapy, smoking, vitamin D deficiency, low 
levels of anabolic hormones (e.g. testosterone), impaired energy balance (as a result of 
inadequate dietary intake and/or elevated energy expenditure due to increased work of 
breathing), ageing, etc. [129]. Many of these factors actually interfere with the muscle protein 
metabolism by reducing contractile protein synthesis and/or triggering its degradation, which 
ultimately leads to muscle atrophy and weakness [129]. 
In contrast to severe COPD, in which weight loss and skeletal muscle mass 
wasting/dysfunction are frequent findings, patients with mild-to-moderate COPD often tend 
to be overweight or obese with coexisting metabolic syndrome [146, 147]. There is some 
evidence of increasing prevalence of overweight and obesity in COPD – in the study by 
Eisner et al. [146] there were 20% overweight and 54% obese patients in a COPD cohort with 
a mean FEV1 58%, and in the study by Cecere et al. [148] 32% of patients were overweight 
(mean FEV1 50%) and 38% obese (mean FEV1 55%). In patients who are overweight or 
obese a higher FM is associated with slower walking speed, greater likelihood of functional 
limitation and increased cardiovascular risk, while higher lean mass-to-fat mass ratio is 
related to the faster walking speed and less limitation [146, 149, 150]. 
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Physical activity together with many other factors (e.g. age, gender, genetics, ethnicity, 
dietary intake, different diseases and medications) affect body composition, but their relation 
is complex: body composition is influenced by exercise capacity and physical activity, and 
vice versa, changes in the body composition (e.g. muscle mass waste or gain, fat tissue 
increase) may have significant impact on physical performance [151-153]. There is strong 
evidence that COPD patients have a lower level and intensity of daily physical activity 
compared to age-matched healthy controls, and even compared to patients with other chronic 
diseases [115, 154]. Although physical inactivity may be present even in a mild disease, it 
becomes more common with increasing COPD severity so that sedentary lifestyle is one of 
the characteristics of advanced COPD [116, 155]. In most patients physical performance is 
limited by the two cardinal symptoms – dyspnoea and/or fatigue. Factors contributing to 
exercise intolerance may be divided into three main categories [79]:  
1) Ventilatory limitation - includes airflow limitation, dynamic hyperinflation, pulmonary gas 
exchange abnormalities, respiratory muscle dysfunction;  
2) Cardiac dysfunction - includes cardiovascular deconditioning, right ventricular 
overload/hypertrophy/failure as a result of an elevated pulmonary vascular resistance, 
compromised left ventricular filling due to right ventricular hypertrophy and interventricular 
septal shifting, tachyarrhythmias;  
3) Peripheral muscle dysfunction - discussed previously. 
In addition, exercise tolerance and physical activity may also be influenced by other factors, 
such as poor motivation, coexistence of anxiety/depression, sociodemographic factors (e.g. 
socioeconomic status, education level, ethnicity), environmental conditions (e.g. weather, 
climate, geographical location), day of the week etc. [132].  
Low physical activity and exercise intolerance have multiple negative clinical implications in 
COPD – they are associated with functional limitation and disability, impaired health-related 
quality of life, increased exacerbation risk, higher hospital admission rate, occurrence of 
anxiety and depression, and increased mortality [117-120, 156-158].  
Although the clinicians are increasingly becoming aware of the importance of physical 
activity, exercise capacity and nutritional status in patients with COPD, in clinical practice 
these are rarely assessed because their determination is time consuming and requires special 
equipment. However, the evaluation of physical performance and body composition would 
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improve overall medical care of COPD patients and enable detection of those who would 
benefit most from the pulmonary rehabilitation program and nutritional counselling.  
Nutrition, metabolism and physical activity have been the topic of intense scientific research 
in many chronic diseases including COPD, but previous studies have mainly investigated 
either physical performance or nutritional status and their independent association with COPD 
severity and prognosis [118, 142, 155]. The main aim of the present study was to investigate 
the relationship between nutritional status and physical performance in COPD, and to assess 
the differences in the nutritional status and body composition in patients with poor and normal 
physical performance. 
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2.  HYPOTHESIS 
 
The hypothesis of the present research is that COPD patients with poor physical performance 
have deficient nutritional status. This hypothesis is supported by the previous observations 
that patients with COPD often have reduced physical activity / exercise capacity, and that 
nutritional abnormalities and body composition changes are common extrapulmonary 
manifestations of this disease.  
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3.  AIMS AND PURPOSE OF THE RESEARCH 
 
General aim  
To compare nutritional status / body composition in COPD patients with poor and normal 
physical performance assessed by the 6MWD, gait speed and daily physical activity 
 
Specific aims 
1) To identify factors associated with malnutrition in patients with COPD 
2) To evaluate physical performance in patients with different forms of nutritional 
abnormality  
3) To evaluate the association between physical activity and severity of COPD assessed by 
the lung function, symptoms severity and exacerbation frequency 
4) To evaluate the correlation between daily physical activity and simple tests of muscle 
function/mass 
5) To evaluate the association between physical activity, body composition and health-related 
quality of life  
6) To evaluate the association between physical activity, body composition and 
anxiety/depression 
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4.  MATERIALS AND METHODOLOGY 
 
4.1. Subjects 
A cross-sectional observational study was conducted in outpatients with moderate to very 
severe COPD in the Dubrava University Hospital, Zagreb, Croatia, from February 2015 to 
June 2016. Patients’ participation in the study was on a voluntary basis, and the participants 
met the following inclusion criteria:  
 Age ≥ 40 years 
 Documented COPD history ≥ 1 year in accordance with the criteria set by the GOLD 
[54] 
 Smokers or ex-smokers with smoking history ≥ 10 pack-years 
 Post-bronchodilator spirometry with FEV1/FVC < 0.70, and FEV1 < 80% predicted 
 Clinically stable (without exacerbations) for at least 3 months prior to enrolment 
The exclusion criteria were concomitant diseases and conditions that might influence 
nutritional status and/or physical performance: 
 Unstable cardiac disease (symptomatic ischaemic heart disease, heart failure, 
uncontrolled arrhythmias) 
 Peripheral artery disease with intermittent claudication 
 Limitation in walking due to neurological or osteomuscular disorder 
 Active malignant disease 
 COPD exacerbation within three months prior to enrolment 
 Asthma 
 Active respiratory disease other than COPD 
 End-stage renal disease 
 Decompensated liver cirrhosis 
 Uncontrolled diabetes 
 Uncontrolled thyroid pathology 
 Dementia 
 Sustained systemic corticosteroid therapy 
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The study was approved by the Ethics Committee of the Dubrava University Hospital, 
Zagreb, and by the Ethics Committee of the School of Medicine, University of Zagreb. Each 
participant gave written informed consent. 
 
4.2. Study design 
Two study visits were scheduled within 7±2 days. At the first visit all protocol-related 
procedures and measurements were performed including demographic and clinical data 
collection, pulmonary function tests, nutritional assessment, and physical performance 
evaluation. Tests of physical performance preceded the lung function tests. 
 
4.2.1.  Demographic and clinical data 
Age, sex, smoking history expressed by pack-years, treatment and duration of COPD were 
recorded, along with the number of COPD exacerbations in the previous year. Based on the 
medical history and electronic health care database the information was obtained on moderate 
COPD exacerbations that required treatment with antibiotics and/or oral corticosteroids in the 
outpatient settings, and severe exacerbations that required hospitalisations. Comorbidities 
were evaluated according to the Charlson index [159]. The mMRC dyspnoea scale (Table 2) 
[36] and CATTM (Figure 1) [37] were used for the assessment of symptoms severity. 
Psychological status was evaluated by the Hospital Anxiety and Depression Scale (HADS), a 
fourteen item scale of which seven items are related to anxiety and the remaining seven to 
depression [160]. The Anxiety and Depression subscale scores enable classification into four 
groups: “normal” (0-7), “mild” (8-10), “moderate” (11-14), and “severe” (15-21). Health-
related quality of life was assessed with the EuroQol questionnaire (EQ-5D-5L) that includes 
the visual analogue scale (VAS), descriptive system and calculation of index values [161]. 
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4.2.2.  Pulmonary function tests 
Pre- and post-bronchodilator spirometry, single-breath DLCO measurement, and body 
plethysmography with lung volumes (Vmax Series Software Version 20-7, VIASYS 
Healthcare Inc., SensorMedics Corporation, USA) were performed according to standards set 
by the ATS/ERS using established reference values [33, 162, 163]. The following lung 
function parameters in absolute and percent predicted values were recorded: FEV1, FVC, 
FEV1/FVC ratio, DLCO, diffusing capacity of the lung for carbon monoxide per litre of 
alveolar volume (DLCO/VA), vital capacity (VC), TLC, RV, RV/TLC ratio.  
Patients were classified as GOLD grade 2, 3 or 4 according to the severity of airflow 
limitation based on the post-bronchodilator FEV1 (Table 1) [5]. The GOLD guidelines 2011-
2016 [54] were applied for ABCD categorisation with respect to the post-bronchodilator 
FEV1, exacerbation history, and symptoms severity assessed by the mMRC dyspnoea scale 
and the CATTM score (Figure 2). 
Arterial blood gases were determined in subjects under resting conditions breathing room air 
(RAPIDLAB 348 pH/Blood Gas Analyzer, Siemens Medical Solutions Diagnostics, USA). 
 
4.2.3.  Nutritional assessment 
Body weight was measured to the nearest 0.1 kg, height to the nearest 0.5 cm and expressed 
in meters, and the BMI was calculated as weight/height squared (kg/m2). The subjects were 
categorised into four groups based on the BMI: underweight (<21 kg/m2), normal weight 
(≥21, <25 kg/m2), overweight (≥25, <30 kg/m2), and obese (≥30 kg/m2). The choice of a cut-
off <21 kg/m2 for underweight is in line with the recommendation given by the ATS/ERS 
based on previous studies reporting a higher mortality in COPD patients with BMI <21 kg/m2 
[101-103].  
Additional anthropometric measurements and calculations were performed by routine 
methods [100, 164, 165]: waist, hip, and calf circumference (CC) (cm); waist-to-hip ratio; 
mid-upper arm circumference (MUAC) (cm); triceps skin fold (TSF) (measured in mm with 
the Harpenden Skinfold Caliper, British Indicators LTD, England); mid-arm muscle 
circumference (MAMC) calculated by the equation MAMC (cm) = MUAC (cm) – 0.314 x 
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TSF (mm); arm muscle area (AMA) calculated by the equation AMA (cm2) = [MUAC (cm) – 
0.314 x TSF (mm)]2 / (4 x 3.14). Measurements of the MUAC, TSF and CC were taken on the 
right side of the body. All anthropometric measurements were performed twice, except for the 
TSF, which was measured in triplicate, and the mean values were recorded.  
Body composition was assessed by the DEXA total body scan (Lunar PRODIGY Primo, 
enCORE Software version 11.1, GE Healthcare), as previously described in section 1.2., and 
the following parameters were obtained: LM (kg), FFM (kg), FM (kg), fat proportion (%), 
BMC (kg), BMD (g/cm2), and the T-score. Additionally, the lean mass index (LMI), the 
FFMI, and the fat mass index (FMI) were calculated by dividing the LM, FFM, and FM, 
respectively, by height squared and expressed in kg/m2.  
For rapid clinical assessment of nutritional status the MNA questionnaire was used, and 
patients were stratified in three categories according to the MNA score: “normal nutritional 
status” (24-30 points), “at risk of malnutrition” (17-23.5 points), and “malnourished” (<17 
points) [166]. 
Venous blood samples were collected and analysed for the following biomarkers using 
commercially available assays: total lymphocyte count (Siemens ADVIA 2120i, Siemens 
Healthcare Diagnostics [Shanghai], Walpole, NJ, USA), serum albumin (Beckman Coulter 
AU2700 plus, Miami, USA), prealbumin (Beckman Coulter AU680, Miami, USA), high-
sensitivity C-reactive protein (hs-CRP) (Beckman Coulter AU2700 plus, Miami, USA), and 
25-hydroxyvitamin D (Siemens ADVIA Centaur XP, Siemens Healthcare Diagnostics 
[Shanghai], Walpole, NJ, USA). All samples were analysed at the central laboratory of the 
Dubrava University Hospital. 
 
4.2.4.  Physical performance and muscle function assessment 
In the evaluation of physical performance and peripheral muscle function seven different 
methods were used.  
The 30-second chair stand test [126] and the timed up and go test [128] were performed as 
previously described in section 1.3. The timed up and go test was repeated with some rest in 
between if needed, and the faster of the two times was recorded. 
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The maximal handgrip strength (kg) was measured with a handheld dynamometer (KERN 
MAP 80K1, Version 1.2 08/2012, KERN & Sohn GmbH, Germany) in a sitting position 
while the hand was unsupported with the elbow at 90° flexion and the underarm and wrist in 
neutral positions [167]. The highest of the six measurements (three with each hand) was used 
in the analysis. 
Ultrasound measurement of quadriceps rectus femoris cross-sectional area (RFCSA) was done 
by the radiologist using a B-mode ultrasonography with an 8 MHz, 5.6 cm linear transducer 
array (General Electric Logiq E9, General Electric Company, WI, USA) according to a 
technique described by Seymour et al. [168]. Briefly, the patient was in a supine position with 
the rested right leg supported in passive extension, and the transducer was placed 
perpendicular to the long axis of the thigh on its superior aspect, three-fifths of the distance 
along a line from the anterior superior iliac spine to the superior patellar border. RFCSA was 
calculated using a planimetric technique after the echogenic line of the rectus femoris was 
outlined manually on a frozen image, and the average of the three consecutive measurements 
was recorded.  
The 4MGS was measured as previously described in section 1.3. [124].  
The 6MWT was performed according to the ATS guidelines as previously explained in 
section 1.3. [123], and the measured 6MWD was used in the analysis. During both walk tests 
the subjects were allowed to use their usual walking aids (e.g. cane), and those with chronic 
respiratory insufficiency (SpO2 < 90% at rest breathing room air) were provided with 
supplemental oxygen from a portable oxygen cylinder that was carried by the examiner 
during the tests.  
At the end of the first visit the patients were supplied with the StepWatch Activity Monitor® 
(SAM) (Modus Health IIc, Washington DC, USA), an ankle-worn accelerometer for the 
assessment of physical activity. The SAM does not provide on-instrument feedback of steps 
walked, and its accuracy in detecting steps has been previously demonstrated in subjects with 
a range of activity levels, including patients with COPD [118, 137]. Patients were instructed 
to wear the SAM during 7±2 consecutive days except while washing and sleeping, to perform 
physical activity as usual, and to return the device at the second study visit when the data 
were downloaded. The days of the study visits, as well as no-wear days (< 8 hours of wear 
time) were excluded from the analysis, and the average daily step count was recorded. 
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4.3. Statistical analysis 
Descriptive statistics were used to describe the study population. Categorical variables are 
presented as absolute numbers (percentages), and continuous variables as means ± standard 
deviations (SD), or medians (1st quartile; 3rd quartile) in the case of non-normal distribution. 
For each measure of physical performance (6MWD, 4MGS, daily physical activity) the 
results were divided in the “poor” and “normal” group with cut-offs of 350 m for the 6MWD, 
0.8 m/s for the 4MGS and the median for the average daily step count in line with previous 
studies [124, 169, 170]. Demographic, clinical and nutritional variables were compared 
between the “poor” and “normal” group. Categorical variables were compared with the Chi 
square or Fisher’s test, while the Student’s t or Mann-Whitney U test were used for 
comparison of continuous variables. The association between independent variables and 
“poor” physical performance was assessed using univariate and multivariate stepwise logistic 
regression analysis. Variables showing a p-value <0.1 in the univariate analysis were included 
in the multivariate models. The correlation between variables was analysed by Pearson’s or 
Spearman’s rank correlation tests. All the tests were conducted at a significance level of α = 
0.05. The SPSS version 20 software (IBM Corp., Armonk, NY) was used for all the analyses. 
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5.  RESULTS 
5.1. Patients’ characteristics 
A total of 112 patients were recruited, and one was excluded because of non-compliance, 
leaving 111 patients for analysis. The patients’ characteristics are presented in Table 4. The 
study population was comprised of 76 (68.5%) men and 35 (31.5%) women, and the mean ± 
SD age was 67.7 ± 7.8 years (range 48-88 years). There were 39 (35%) smokers and 72 (65%) 
ex-smokers with a cumulative smoking history of 43.9 ± 24.8 pack-years.  
On average, patients had been treated for COPD 9.1 ± 7.4 years, and 42 (37.8%) patients had 
had at least one moderate or severe COPD exacerbation in the previous year (mean number of 
moderate/severe exacerbations was 1.2 ± 1.4, maximum 8). According to the pulmonary 
function tests the average patient had moderately severe airflow obstruction (mean post-
bronchodilator FEV1 48.9 ± 15.0% pred., FEV1/FVC 0.43 ± 0.11), lung hyperinflation (TLC 
110.5 ± 24.6% pred., RV 159.5 ± 62.2% pred., RV/TLC 55.0 ± 13.2%, RV/TLC 134.5 ± 
31.6% pred.), mild-to-moderate decrease in diffusing capacity (DLCO 50.5 ± 19.3% pred., 
DLCO/VA 70.3 ± 22.9% pred.), and mild hypoxemia (pO2 9.2 ± 1.4 kPa, SatO2 93.2 ± 
3.7%). Regarding symptoms severity the mean CAT score was 17.9 ± 6.4 and mMRC 
dyspnoea grade 2.0 ± 1.0.  
The Charlson comorbidity index was 1.8 ± 1.0, while the mean HADS scores on anxiety and 
depression were within the normal range. The health-related quality of life of the study 
population was impaired with an EQ-5D-5L index value of 0.7 ± 0.2, and EQ-5D-5L VAS 
score of 57.9 ± 15.2.  
GOLD categorisation of the study population is depicted in Figure 7. According to the 
severity of airflow obstruction the most prevalent were GOLD 2 (47%) and GOLD 3 (42%) 
categories, and when symptoms and exacerbations were considered the majority of patients 
were in the GOLD groups B (29%) and D (61%). Frequency of the different therapies used in 
the study population are presented in Figure 8. LABA, LAMA and SABA were the most 
commonly used COPD medications.  
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 Table 4. Baseline characteristics of the study population (n = 111). 
Data are presented as means ± standard deviation or numbers (%), as appropriate. 
Abbreviations: CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary disease; DLCO: diffusing 
capacity of the lung for carbon monoxide; DLCO/VA: diffusing capacity of the lung for carbon monoxide per 
litre of alveolar volume; EQ-5D-5L: EuroQol questionnaire; FEV1: forced expiratory volume in one second; 
FEV1/FVC: ratio of forced expiratory volume in one second to forced vital capacity; FVC: forced vital capacity; 
HADS: Hospital Anxiety and Depression Scale; mMRC: modified Medical Research Council; pCO2: partial 
pressure of carbon-dioxide in arterial blood; pO2: partial pressure of oxygen in arterial blood; Post: post-
bronchodilator; pred: predicted; RV: residual volume; RV/TLC: ratio of residual volume to total lung capacity; 
SatO2: arterial oxygen saturation; TLC: total lung capacity; VAS: visual analogue scale; VC: vital capacity. 
 
 
 
 
 
 
 
Demographic and clinical 
parameters 
 
 
Pulmonary function   
Age, years 67.7 ± 7.8 Post FVC, % pred. 90.8 ± 19.0 
Sex  Post FEV1, % pred. 48.9 ± 15.0 
      Male 
      Female 
76 (68.5) 
35 (31.5) Post FEV1/FVC 
0.43 ± 0.11 
Smoking history, pack-years 43.9 ± 24.8 VC, % pred. 85.1 ± 19.1 
Treated for COPD, years 9.1 ± 7.4 TLC, % pred. 110.5 ± 24.6 
COPD exacerbations in the 
previous year 
1.2 ± 1.4 RV, % pred. 159.5 ± 62.2 
mMRC dyspnoea scale 2.0 ± 1.0 RV/TLC, % 55.0 ± 13.2 
CAT score 17.9 ± 6.4 RV/TLC, % pred. 134.5 ± 31.6 
Charlson comorbidity index 1.8 ± 1.0 DLCO, % pred. 50.5 ± 19.3 
HADS Anxiety score 6.8 ± 4.1 DLCO/VA, % pred. 70.3 ± 22.9 
HADS Depression score 7.3 ± 3.5 pO2, kPa 9.2 ± 1.4 
EQ-5D-5L index value 0.7 ± 0.2 pCO2, kPa 5.6 ± 0.7 
EQ-5D-5L VAS 57.9 ± 15.2 SatO2, % 93.2 ± 3.7 
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Figure 7. GOLD categorisation of the study population.  
Abbreviations: GOLD: Global Initiative for Chronic Obstructive Lung Disease. 
    
 
43 
 
 
Figure 8. Frequency of different therapeutic options in the study population. 
Abbreviations: ICS: inhaled corticosteroids; LABA: long-acting beta2-agonists; LAMA: 
long-acting muscarinic antagonists; LTOT: long-term oxygen therapy; SABA: short-acting 
beta2-agonists; SAMA: short-acting muscarinic antagonists. 
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5.2. Physical performance of the study population 
The results of the physical performance and muscle function tests for the study population are 
presented in Table 5. On average, in the 6MWT patients achieved 376 ± 119 m (range 78-627 
m), and 0.89 ± 0.22 m/s (range 0.33-1.35 m/s) in the 4MGS. The average daily step count for 
the study population was 8059 ± 4757 steps/day, but ranged from extremely poor (minimum 
220 steps/day) to excellent (maximum 23342 steps/day). 
A very strong correlation was found between the 6MWD and the 4MGS (Pearson coefficient r 
= 0.852, p<0.001). The correlation between physical activity and the 6MWD was strong (r = 
0.681, p<0.001), while the correlation between physical activity and the 4MGS was moderate 
(r = 0.451, p<0.001).  
The mean number of rises in the 30-second chair stand test was 11 ± 3, while the mean result 
in the timed up and go test for the study population was 10.3 ± 3.3 s. The rest of the variables 
related to muscle function can be found in Table 5. 
 
 
Table 5. Physical performance and muscle function tests results for the study population. 
 
Parameter 
 
 
6-minute walk distance, m 376 ± 119 
4-metre gait speed, m/s 0.89 ± 0.22 
Physical activity, steps/day 8059 ± 4757 
30-second chair stand test, number of rises 11 ± 3 
Timed up and go test, s 10.3 ± 3.3 
Handgrip strength – right hand, kg 30.7 ± 10.1 
Handgrip strength – left hand, kg 29.1 ± 9.2 
Rectus femoris cross-sectional area, cm2 6.0 ± 1.8 
Data are presented as means ± standard deviation. 
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5.3. Nutritional status of the study population 
The mean BMI was 27.1 ± 5.8 kg/m2, and MNA score 24.0 ± 3.3. The stratification of the 
study population based on the BMI and MNA scores is depicted in Figure 9. 
 
 
Figure 9. Nutritional status of the study population assessed by the body mass index (Fig 9A) 
and the Mini Nutritional Assessment questionnaire (Fig 9B). Data are presented as number of 
patients (%) for each category.  
 
 
 
The average values of the anthropometric measurements, MNA score, DEXA parameters and 
laboratory findings of the study population are presented in Table 6. Mean serum vitamin D 
concentration was 40.0 ± 18.2 nmol/L, and 86 patients (77%) were vitamin D deficient (serum 
vitamin D level < 50 nmol/L). 
The mean FFMI for the study population was 18.3 ± 2.7 kg/m2, and FFM depletion (FFMI 
<15 kg/m2 for women, <16 kg/m2 for men,) was more prevalent in women (37%) than in men 
(4%) – Figure 10.  
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Table 6. Nutritional parameters of the study population. 
Data are presented as means ± standard deviation.  
Abbreviations: DEXA: dual energy X-ray absorptiometry; hs-CRP: high-sensitivity C-reactive protein; MNA: 
Mini Nutritional Assessment. 
 
 
 
Figure 10. Prevalence of reduced fat-free mass index (FFMI) in male and female patients. 
Data are presented as number of patients (%). 
Anthropometric measurements 
and MNA score 
 DEXA and laboratory 
parameters  
 
  Lean mass index, kg/m2 17.4 ± 2.6 
Body mass index, kg/m2 27.1 ± 5.8 Fat-free mass index, kg/m2 18.3 ± 2.7 
Waist circumference, cm 97.3 ± 15.2 Fat mass index, kg/m2 8.8 ± 4.1 
Hip circumference, cm 99.4 ± 10.0 Fat proportion, % 30.9 ± 9.7 
Waist-to-hip ratio  1.0 ± 0.1 Bone mineral content, kg 2.6 ± 0.6 
Calf circumference, cm 35.6 ± 4.2 Bone mineral density, g/cm2 1.1 ± 0.1 
Mid-upper arm 
circumference, cm 
29.8 ± 4.5 T-score -1.0 ± 1.5 
Triceps skin fold, mm 16.8 ± 8.0   
Mid-arm muscle  
circumference, cm 
24.5 ± 3.2 Lymphocyte count, x109/L 2.0 ± 0.7 
Arm muscle area, cm2 48.6 ± 12.5 Albumin, g/L 46.2 ± 3.4 
  Prealbumin, g/L 21.7 ± 4.7 
MNA score 24.0 ± 3.3 hs-CRP, mg/L 6.9 ± 11.3 
  Vitamin D, nmol/L 40.0 ± 18.2 
    
 
47 
 
5.4. Comparison of patients with poor and normal exercise capacity 
Fifty-three (48%) patients had poor exercise capacity defined by the 6MWD ≤ 350 m, and in 
comparison to those with normal exercise capacity (6MWD > 350 m) they were significantly 
older, had worse lung function, a higher CAT score and a higher mMRC dyspnoea level 
(p<0.05) (Table 7). Additionally, they had been treated longer for COPD, had more 
exacerbations, worse health-related quality of life, as well as a higher HADS Depression 
score (p<0.05). There was a higher proportion of women in the group of patients with 6MWD 
≤ 350 m than in the group with 6MWD > 350 m. Patients with poor exercise capacity also had 
a significantly slower gait speed and lower daily step counts (Table 7).  
Comparison of nutritional parameters is presented in Table 8. Patients with low exercise 
capacity had a lower LMI, FFMI, BMC, BMD, and T-score (p<0.05). Among anthropometric 
measurements they had a significantly smaller CC, MUAC, MAMC and AMA. Furthermore, 
they had a lower MNA score, as well as lower serum albumin and prealbumin levels (p<0.05). 
The factors that were independently and significantly related to low exercise capacity in the 
multivariate analysis were age, previous exacerbations, RV/TLC ratio, DLCO/VA, and 
mMRC dyspnoea level (Table 9). The multivariate model showed good goodness-of-fit (P-
value of 0.608 in the Hosmer-Lemeshow test) and a good predictive power (area under the 
curve [AUC] = 0.922; p<0.001) (Figure 11). 
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Table 7. Characteristics of patients with poor and normal exercise capacity based on the 6-
minute walk distance (6MWD). 
Data are presented as means ± standard deviation or numbers (%), as appropriate. 
* statistically significant (p <0.05) 
Abbreviations: CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary disease; DLCO/VA: 
diffusing capacity of the lung for carbon monoxide per litre of alveolar volume; EQ-5D-5L: EuroQol 
questionnaire; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HADS: Hospital 
Anxiety and Depression Scale; 4MGS: 4-metre gait speed; mMRC: modified Medical Research Council; 6MWD: 
6-minute walk distance; pCO2: partial pressure of carbon-dioxide in arterial blood; pO2: partial pressure of oxygen 
in arterial blood; Post: post-bronchodilator; pred: predicted; RV: residual volume; RV/TLC: ratio of residual 
volume to total lung capacity; TLC: total lung capacity; VAS: visual analogue scale.  
 
Parameter 
 
Patients with 
6MWD ≤ 350 m 
(n=53) 
 
Patients with 
6MWD > 350 m 
(n=58) 
 
p-value 
Age, years 70.1 ± 7.5 65.5 ± 7.4 0.002* 
Sex 
      Male 
      Female 
 
30 (56.6) 
23 (43.4) 
 
46 (79.3) 
12 (20.7) 
0.010* 
Smoking history, pack-years 41.5 ± 24.2 46.2 ± 25.3 0.325 
Treated for COPD, years 12.1± 7.4 6.3 ± 6.3 <0.001* 
COPD exacerbations in the previous year 1.8 ± 1.5 0.7 ± 1.0 <0.001* 
mMRC dyspnoea scale 2.6 ± 0.8 1.4 ± 0.7 <0.001* 
CAT score 20.9 ± 5.9 15.2 ± 5.7 <0.001* 
Post FVC, % pred. 87.6 ± 20.3 93.8 ± 17.5 0.087 
Post FEV1, % pred. 43.2 ± 13.6 54.1 ± 14.5 <0.001* 
TLC, % pred. 115.4 ± 28.3 106.2 ± 20.1 0.051 
RV, % pred. 177.6 ± 66.4 143.6 ± 53.9 0.004* 
RV/TLC, % 60.5 ± 13.3 50.2 ± 11.2 <0.001* 
DLCO/VA, % pred. 63.4 ± 21.3 76.6 ± 22.8 0.002* 
pO2, kPa 8.7 ± 1.6 9.7 ± 1.2 0.001* 
pCO2, kPa 5.7 ± 0.8 5.5 ± 0.6 0.108 
Charlson comorbidity index 1.8 ± 1.1 1.7 ± 1.0 0.946 
HADS Anxiety score 7.6 ± 4.3 6.1 ± 3.8  0.055 
HADS Depression score 8.5 ± 3.7 6.2 ± 3.0 <0.001* 
EQ-5D-5L index value 0.7 ± 0.2 0.8 ± 0.1 <0.001* 
EQ-5D-5L VAS 51.9 ± 15.0 63.4 ± 13.4 <0.001* 
4MGS, m/s 0.74 ± 0.18 1.04 ± 0.14 <0.001* 
6MWD, m 274 ± 78 469 ± 59 <0.001* 
Physical activity, steps/day 5366 ± 3080 10519 ± 4703 <0.001* 
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Table 8. Comparison of nutritional status between patients with poor and normal exercise 
capacity based on the 6-minute walk distance (6MWD). 
Data are presented as means ± standard deviation. 
* statistically significant (p <0.05) 
Abbreviations: hs-CRP: high-sensitivity C-reactive protein; MNA: Mini-Nutritional Assessment; 6MWD: 6-
minute walk distance. 
 
 
 
 
Parameter 
 
Patients with 
6MWD ≤ 350 m 
(n=53) 
 
Patients with 
6MWD > 350 m 
(n=58) 
 
p-value 
Body mass index, kg/m2 26.6 ± 6.3 27.6 ± 5.3 0.388 
Waist circumference, cm 95.3 ± 15.4 99.1 ± 14.9 0.190 
Hip circumference, cm 98.5 ± 10.3 100.3 ± 9.7 0.343 
Waist-to-hip ratio  1.0 ± 0.1 1.0 ± 0.1 0.242 
Calf circumference, cm 34.5 ± 4.1 36.5 ± 4.2 0.013* 
Mid-upper arm circumference, cm 28.8 ± 4.6 30.7 ± 4.2 0.026* 
Triceps skin fold, mm 16.6 ± 8.3 17.0 ± 7.8 0.776 
Mid-arm muscle circumference, cm 23.6 ± 3.2 25.3 ± 3.0 0.003* 
Arm muscle area, cm2 45.0 ± 12.1 51.8 ± 12.1 0.004* 
Lean mass index, kg/m2 16.7 ± 2.6 18.0 ± 2.4 0.006* 
Fat-free mass index, kg/m2 17.6 ± 2.8 19.0 ± 2.5 0.006* 
Fat mass index, kg/m2 8.9 ± 4.4 8.6 ± 3.8 0.662 
Fat proportion, % 32.0 ± 10.2 29.9 ± 9.2 0.266 
Bone mineral content, kg  2.4 ± 0.6 2.7 ± 0.6 0.003* 
Bone mineral density, g/cm2 1.07 ± 0.1 1.15 ± 0.1 0.002* 
T-score -1.4 ± 1.4 -0.7 ± 1.5 0.013* 
MNA score 23.1 ± 3.5 24.9 ± 2.9 0.004* 
Lymphocyte count, x109/L 1.9 ± 0.7 2.0 ± 0.7 0.359 
Albumin, g/L 45.4 ± 3.0 46.8 ± 3.6 0.026* 
Prealbumin, g/L 20.6 ± 4.8 22.7 ± 4.5 0.017* 
hs-CRP, mg/L 7.8 ± 13.1 6.1 ± 9.5 0.415 
Vitamin D, nmol/L 39.1 ± 16.5 40.9 ± 19.7 0.605 
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Table 9. Univariate and multivariate logistic regression analysis for the prediction of poor 
exercise capacity defined by the 6-minute walk distance ≤ 350 m. 
Abbreviations: BMD: bone mineral density; CAT: COPD Assessment Test; COPD: chronic obstructive 
pulmonary disease; CI: confidence interval; DLCO/VA: diffusing capacity of the lung for carbon monoxide per 
litre of alveolar volume; EQ-5D-5L: EuroQol questionnaire; FEV1: forced expiratory volume in one second; 
FFMI: fat-free mass index; HADS: Hospital Anxiety and Depression Scale; LMI: lean mass index; mMRC: 
modified Medical Research Council; MNA: Mini-Nutritional Assessment; 6MWD: 6-minute walk distance; OR: 
odds ratio; pO2: partial pressure of oxygen in arterial blood; pred: predicted; RV/TLC: ratio of residual volume to 
total lung capacity.  
 
 
 
                   
               Univariate 
 
                  Multivariate  
 
 
Variable OR (95% CI) p-value OR (95% CI) p-value 
Age (years) 1.086 (1.029-1.147) 0.003 1.229 (1.090-1.385) <0.001 
 
 
 
 
 
Sex (female) 2.939 (1.274-6.780) 0.011  
Previous exacerbations 4.384 (1.898-10.168) 0.001 4.216 (1.064-16.700) 0.040 
 FEV1 (% pred.) 0.983 (0.963-1.003) 0.089   
RV/TLC (%) 1.079 (1.038-1.182) 0.001 1.026 (1.002-1.052) 0.007 
DLCO/VA (% pred.) 0.973 (0.955-0.991) 0.003 0.939 (0.899-0.980) 0.007 
HADS Depression score 2.138 (0.981-4.596) 0.050   
CAT score 1.181 (1.095-1.275) <0.001   
EQ-5D-5L index value 0.007 (0.001-0.102) 0.001   
mMRC dyspnoea scale 9.382 (3.690-23.851) 0.001 7.389 (2.600-20.994) <0.001 
MNA 0.835 (0.735-0.908) 0.005   
FFMI (kg/m2) 0.814 (0.700-0.954) 0.008   
LMI (kg/m2) 0.809 (0.691-0.947) 0.008   
BMD (g/cm2) 0.010 (0.001-0.230) 0.004   
pO2 (kPa) 0.809 (0.772-0.820) 0.001   
Albumin (g/L) 0.873 (0.772-0.988) 0.032   
Prealbumin (g/L) 0.904 (0.831-0.984) 0.020   
Arm muscle area (cm2) 0.954 (0.923-0.987) 0.006   
Calf circumference (cm) 0.889 (0.808-0.978) 0.016   
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Figure 11. Receiver operating characteristic analysis of significant variables derived from the 
multivariate logistic regression model and their capacity to predict poor exercise capacity 
defined by the 6-minute walk distance ≤ 350 m. The model includes age, moderate/severe 
exacerbations in the previous year, ratio of residual volume to total lung capacity (RV/TLC), 
diffusing capacity of the lung for carbon monoxide per litre of alveolar volume (DLCO/VA), 
and mMRC dyspnoea level.  
Abbreviations: AUC: area under the curve; CI: confidence interval; SE: standard error. 
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5.5. Comparison of patients with slow and normal gait speed 
Thirty-six (32%) patients had slow gait speed defined by the 4MGS < 0.8 m/s. When 
compared to those with normal gait speed, patients with slow gait speed were significantly 
older, had a longer history of COPD, worse lung function, more frequent exacerbations, and a 
higher symptom burden assessed by the CAT and the mMRC dyspnoea scale (p<0.05) (Table 
10). Moreover, patients with slow gait speed had worse health-related quality of life based on 
the results in the EuroQol questionnaire, and a higher HADS Depression score (p<0.05). 
Women were more prevalent in the group of patients with 4MGS < 0.8 m/s than in the group 
with 4MGS ≥ 0.8 m/s. In addition, patients with slow gait speed had a significantly worse 
exercise capacity (i.e. shorter 6MWD) and lower daily step counts (Table 10). 
Comparison of nutritional parameters is presented in Table 11. Patients with slow gait speed 
had a lower LMI, FFMI, BMC, BMD, T-score, and a lower MNA score (p<0.05). 
Anthropometric assessment has revealed a significantly smaller CC, MAMC and AMA in 
patients with 4MGS < 0.8 m/s.  
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Table 10. Characteristics of patients with slow and normal gait speed based on the 4-metre  
gait speed (4MGS) test. 
Data are presented as means ± standard deviation or numbers (%), as appropriate. 
* statistically significant (p <0.05) 
Abbreviations: CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary disease; DLCO/VA: 
diffusing capacity of the lung for carbon monoxide per litre of alveolar volume; EQ-5D-5L: EuroQol 
questionnaire; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HADS: Hospital 
Anxiety and Depression Scale; 4MGS: 4-metre gait speed; mMRC: modified Medical Research Council; 
6MWD: 6-minute walk distance; pCO2: partial pressure of carbon-dioxide in arterial blood; pO2: partial pressure 
of oxygen in arterial blood; Post: post-bronchodilator; pred: predicted; RV: residual volume; RV/TLC: ratio of 
residual volume to total lung capacity; TLC: total lung capacity; VAS: visual analogue scale.  
 
Parameter 
 
Patients with 
4MGS < 0.8 m/s 
(n=36) 
 
Patients with 
4MGS ≥ 0.8 m/s 
(n=75) 
 
p-value 
Age, years 70.0 ± 8.2 66.6 ± 7.4 0.032* 
Sex 
      Male 
      Female 
 
18 (50.0) 
18 (50.0) 
 
58 (77.3) 
17 (22.7) 
0.004* 
Smoking history, pack-years 40.6 ± 24.1 45.5 ± 25.1 0.333 
Treated for COPD, years 12.7± 8.2 7.3 ± 6.3 0.001* 
COPD exacerbations in the previous year 1.9 ± 1.7 0.9 ± 1.1 <0.001* 
mMRC dyspnoea scale 2.7 ± 0.9 1.6 ± 0.7 <0.001* 
CAT score 20.8 ± 5.8 16.6 ± 6.3 0.001* 
Post FVC, % pred. 86.1 ± 22.1 93.1 ± 17.1 0.102 
Post FEV1, % pred. 42.3 ± 15.1 52.1 ± 14.0 0.001* 
TLC, % pred. 115.4 ± 31.1 108.2 ± 20.8 0.157 
RV, % pred. 179.4 ± 69.8 150.1 ± 56.3 0.021* 
RV/TLC, % 61.1 ± 14.9 52.1 ± 11.4 0.001* 
DLCO/VA, % pred. 61.5 ± 22.1 74.5 ± 22.3 0.005* 
pO2, kPa 8.7 ± 1.7 9.5 ± 1.3 0.013* 
pCO2, kPa 5.7 ± 0.8 5.5 ± 0.7 0.141 
Charlson comorbidity index 1.8 ± 1.2 1.7 ± 0.9 0.547 
HADS Anxiety score 7.3 ± 3.9 6.6 ± 4.2  0.411 
HADS Depression score 8.3 ± 3.8 6.8 ± 3.3 0.033* 
EQ-5D-5L index value 0.6 ± 0.2 0.8 ± 0.1 <0.001* 
EQ-5D-5L VAS 50.6 ± 14.1 61.4 ± 14.6 <0.001* 
4MGS, m/s 0.65 ± 0.14 1.01 ± 0.13 <0.001* 
6MWD, m 251 ± 85 436 ± 81 <0.001* 
Physical activity, steps/day 5340 ± 3356 9364 ± 4794 <0.001* 
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Table 11. Comparison of nutritional status between patients of with slow and normal gait 
speed based on the 4-metre gait speed (4MGS) test. 
Data are presented as means ± standard deviation. 
* statistically significant (p <0.05) 
Abbreviations: hs-CRP: high-sensitivity C-reactive protein; 4MGS: 4-metre gait speed; MNA: Mini-Nutritional 
Assessment. 
 
Parameter 
 
Patients with  
4MGS < 0.8 m/s 
(n=36) 
 
Patients with  
4MGS ≥ 0.8 m/s 
(n=75) 
 
p-value 
Body mass index, kg/m2 26.3 ± 6.0 27.5 ± 5.7 0.300 
Waist circumference, cm 94.3 ± 14.6 98.7 ± 15.3 0.150 
Hip circumference, cm 98.0 ± 10.1 100.1 ± 9.9 0.293 
Waist-to-hip ratio  1.0 ± 0.1 1.0 ± 0.1 0.257 
Calf circumference, cm 33.9 ± 4.2 36.4 ± 4.1 0.004* 
Mid-upper arm circumference, cm 28.6 ± 4.4 30.4 ± 4.4 0.051 
Triceps skin fold, mm 16.7 ± 8.2 16.9 ± 7.9 0.870 
Mid-arm muscle circumference, cm 23.4 ± 3.0 25.0 ± 3.1 0.009* 
Arm muscle area, cm2 44.1 ± 11.3 50.7 ± 12.6 0.009* 
Lean mass index, kg/m2 16.3 ± 2.4 17.9 ± 2.5 0.002* 
Fat-free mass index, kg/m2 17.2 ± 2.5 18.8 ± 2.6 0.002* 
Fat mass index, kg/m2 9.0 ± 4.4 8.7 ± 3.9 0.678 
Fat proportion, % 32.6 ± 10.8 30.1 ± 9.2 0.208 
Bone mineral content, kg  2.3 ± 0.6 2.7 ± 0.6 0.009* 
Bone mineral density, g/cm2 1.05 ± 0.1 1.14 ± 0.1 0.002* 
T-score -1.5 ± 1.4 -0.8 ± 1.5 0.017* 
MNA score 22.5 ± 3.6 24.8 ± 2.9 0.001* 
Lymphocyte count, x109/L 1.9 ± 0.7 2.0 ± 0.7 0.314 
Albumin, g/L 45.5 ± 3.2 46.5 ± 3.5 0.155 
Prealbumin, g/L 21.0 ± 5.1 22.0 ± 4.5 0.275 
hs-CRP, mg/L 8.5 ± 15.3 6.1 ± 8.9 0.302 
Vitamin D, nmol/L 38.9 ± 17.5 40.6 ± 18.6 0.642 
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5.6. Comparison of patients with poor and normal physical activity 
Fifty-six (50%) patients had poor physical activity defined by the daily step count ≤ 7128 
steps/day, and in comparison to those with normal physical activity they were significantly 
older, had a longer history of COPD, more frequent exacerbations, worse lung function, more 
severe respiratory symptoms based on the CAT score and mMRC dyspnoea level, and worse 
health-related quality of life (p<0.05). They also had a slower gait speed and a shorter 6MWD 
(Table 12). 
Comparison of nutritional parameters is presented in Table 13. Among anthropometric 
measurements patients with low physical activity had a significantly smaller CC, MAMC and 
AMA, and when analysing body composition they had a lower LMI and FFMI (p<0.05). 
Furthermore, they had a significantly lower MNA score, as well as lower serum prealbumin 
and vitamin D levels (p<0.05). 
The factors that were independently and significantly related to low physical activity in the 
multivariate analysis were age, DLCO/VA, and mMRC dyspnoea level (Table 14). The 
multivariate model was well calibrated (P-value of 0.331 in the Hosmer-Lemeshow test) and 
showed a good predictive power (AUC = 0.840; p<0.001) (Figure 12). 
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Table 12. Characteristics of patients with poor and normal physical activity based on the  
average daily step count. 
Data are presented as means ± standard deviation or numbers (%), as appropriate. 
* statistically significant (p <0.05) 
Abbreviations: CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary disease; DLCO/VA: 
diffusing capacity of the lung for carbon monoxide per litre of alveolar volume; EQ-5D-5L: EuroQol 
questionnaire; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HADS: Hospital 
Anxiety and Depression Scale; 4MGS: 4-metre gait speed; mMRC: modified Medical Research Council; 
6MWD: 6-minute walk distance; pCO2: partial pressure of carbon-dioxide in arterial blood; pO2: partial pressure 
of oxygen in arterial blood; Post: post-bronchodilator; pred: predicted; RV: residual volume; RV/TLC: ratio of 
residual volume to total lung capacity; TLC: total lung capacity; VAS: visual analogue scale.  
 
Parameter 
Patients with  
≤ 7128 steps/day   
(n=56) 
Patients with  
> 7128 steps/day   
(n=55) 
p-value 
Age, years 69.3 ± 7.1 66.1 ± 8.1 0.026* 
Sex 
      Male 
      Female 
 
37 (66.1) 
19 (33.9) 
 
39 (70.9) 
16 (29.1) 
0.538 
Smoking history, pack-years 42.0 ± 24.5 45.9 ± 25.2 0.415 
Treated for COPD, years 11.0 ± 7.3 7.1 ± 7.0 0.006* 
COPD exacerbations in the previous year 1.6 ± 1.6 0.8 ± 1.0 0.002* 
mMRC dyspnoea scale 2.5 ± 1.0 1.5 ± 0.6 <0.001* 
CAT score 20.0 ± 6.1 15.8 ± 6.1 0.001* 
Post FVC, % pred. 87.3 ± 20.7 94.5 ± 16.6 0.046* 
Post FEV1, % pred. 43.5 ± 14.6 54.5 ± 13.5 <0.001* 
TLC, % pred. 115.4 ± 28.0 105.8 ± 20.1 0.043* 
RV, % pred. 176.1 ± 69.7 143.2 ± 49.2 0.006* 
RV/TLC, % 58.5 ± 14.4 51.5 ± 11.0 0.005* 
DLCO/VA, % pred. 64.2 ± 21.2 76.5 ± 23.2 0.004* 
pO2, kPa 8.9 ± 1.6 9.6 ± 1.2 0.006* 
pCO2, kPa 5.7 ± 0.8 5.4 ± 0.5 0.033* 
Charlson comorbidity index 1.8 ± 1.1 1.7 ± 0.9 0.450 
HADS Anxiety score 7.0 ± 4.3 6.6 ± 4.0  0.579 
HADS Depression score 7.8 ± 3.5 6.8 ± 3.5 0.108 
EQ-5D-5L index value 0.7 ± 0.2 0.8 ± 0.2 0.001* 
EQ-5D-5L VAS 54.0 ± 16.4 61.8 ± 13.0 0.006* 
4MGS, m/s 0.82 ± 0.22 0.97 ± 0.19 <0.001* 
6MWD, m 316 ± 110 437 ± 95 <0.001* 
Physical activity, steps/day 4403 ± 1662 11781 ± 3912 <0.001* 
    
 
57 
 
Table 13. Comparison of nutritional status between patients of with poor and normal physical 
activity based on the average daily step count. 
Data are presented as means ± standard deviation. 
* statistically significant (p <0.05) 
Abbreviations: hs-CRP: high-sensitivity C-reactive protein; MNA: Mini-Nutritional Assessment. 
 
Parameter 
 
Patients with  
≤ 7128 steps/day   
(n=56) 
 
Patients with  
> 7128 steps/day   
(n=55) 
 
p-value 
Body mass index, kg/m2 26.6 ± 6.0 27.7 ± 5.6 0.313 
Waist circumference, cm 96.5 ± 15.0 98.1 ± 15.5 0.589 
Hip circumference, cm 98.9 ± 10.0 99.9 ± 10.0 0.581 
Waist-to-hip ratio  1.0 ± 0.1 1.0 ± 0.1 0.748 
Calf circumference, cm 34.7 ± 3.9 36.5 ± 4.4 0.028* 
Mid-upper arm circumference, cm 29.1 ± 4.4 30.4 ± 4.5 0.132 
Triceps skin fold, mm 16.7 ± 8.5 16.9 ± 7.5 0.884 
Mid-arm muscle circumference, cm 23.9 ± 2.8 25.1 ± 3.5 0.045* 
Arm muscle area, cm2 46.1 ± 10.7 51.1 ± 13.8 0.033* 
Lean mass index, kg/m2 16.8 ± 2.5 17.9 ± 2.5 0.027* 
Fat-free mass index, kg/m2 17.7 ± 2.6 18.9 ± 2.7 0.026* 
Fat mass index, kg/m2 8.8 ± 4.3 8.8 ± 3.8 0.977 
Fat proportion, % 31.3 ± 10.8 30.5 ± 8.6 0.673 
Bone mineral content, kg  2.5 ± 0.6 2.6 ± 0.6 0.176 
Bone mineral density, g/cm2 1.09 ± 0.1 1.13 ± 0.1 0.074 
T-score -1.3 ± 1.5 -0.8 ± 1.5 0.072 
MNA score 23.3 ± 3.4 24.7 ± 3.0 0.022* 
Lymphocyte count, x109/L 1.9 ± 0.7 2.1 ± 0.7 0.210 
Albumin, g/L 46.0 ± 2.8 46.4 ± 3.9 0.537 
Prealbumin, g/L 20.7 ± 4.2 22.7 ± 5.1 0.032* 
hs-CRP, mg/L 7.0 ± 9.3 6.9 ± 13.2 0.961 
Vitamin D, nmol/L 34.7 ± 16.2 45.5 ± 18.6 0.001* 
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Table 14. Univariate and multivariate logistic regression analysis for the prediction of poor 
physical activity defined by the daily step count ≤ 7128 steps/day.  
  
                Univariate 
                     
Multivariate  
 
 
 
Variable 
OR (95% CI) p-value OR (95% CI) p-value 
Age (years) 1.059 (1.006-1.115) 0.029 1.086 (1.013-1.163) 0.021 
Previous exacerbations 2.636 (1.192-5.826) 0.017   
FEV1 (% pred.) 0.979 (0.959-1.000) 0.049   
RV/TLC (%) 1.014 (1.000-1.027) 0.044   
DLCO/VA (% pred.) 0.975 (0.957-0.983) 0.006 0.975 (0.953-0.997) 0.026 
HADS Depression score 1.300 (0.612-2.760) 0.049   
CAT score 1.117 (1.045-1.194) <0.001   
EQ-5D-5L index value 0.023 (0.002-0.258) 0.001   
mMRC dyspnoea scale 5.177 (2.543-10.546) 0.001 4.332 (2.124-8.833) <0.001 
MNA 0.870 (0.769-0.983) 0.026   
FFMI (kg/m2) 0.850 (0.734-0.984) 0.029   
LMI (kg/m2) 0.844 (0.724-0.983) 0.030   
BMD (g/cm2) 0.074 (0.004-1.317) 0.076   
pO2 (kPa) 0.680 (0.512-0.902) 0.007   
Prealbumin (g/L) 0.914 (0.841-0.994) 0.035   
Vitamin D (nmol/L) 0.964 (0.942-0.987) 0.003   
Arm muscle area (cm2) 0.967 (0.937-0.998) 0.036   
Calf circumference (cm) 0.074 (0.004-1.317) 0.076   
Abbreviations: BMD: bone mineral density; CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary 
disease; CI: confidence interval; DLCO/VA: diffusing capacity of the lung for carbon monoxide per litre of alveolar 
volume; EQ-5D-5L: EuroQol questionnaire; FEV1: forced expiratory volume in one second; FFMI: fat-free mass 
index; HADS: Hospital Anxiety and Depression Scale; LMI: lean mass index; mMRC: modified Medical Research 
Council; MNA: Mini-Nutritional Assessment; OR: odds ratio; pO2: partial pressure of oxygen in arterial blood; 
pred: predicted; RV/TLC: ratio of residual volume to total lung capacity.  
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Figure 12. Receiver operating characteristic analysis of significant variables derived from the 
multivariate logistic regression model and their capacity to predict poor physical activity 
defined by the daily step count ≤ 7128 steps/day. The model includes age, diffusing capacity 
of the lung for carbon monoxide per litre of alveolar volume (DLCO/VA) and mMRC 
dyspnoea level.  
Abbreviations: AUC: area under the curve; CI: confidence interval; SE: standard error. 
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5.7. Evaluation of factors associated with malnutrition in patients with 
COPD 
Eighteen (16%) patients were underweight (BMI < 21 kg/m2) and in comparison to patients 
with BMI ≥ 21 kg/m2 they had more severe lung hyperinflation (i.e. higher TLC, RV, and 
RV/TLC), and more pronounced reduction in lung diffusing capacity (i.e. lower DLCO/VA) 
(p<0.05) (Table 15). Underweight patients also had more severe airflow limitation (i.e. lower 
FEV1), however this difference did not reach statistical significance (p=0.058).  
There were no significant differences between underweight patients and the rest of the study 
population regarding age, sex ratios, smoking history, COPD duration, symptoms severity, 
frequency of COPD exacerbations, comorbidities, psychological status, and health-related 
quality of life (Table 15).  
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Table 15. Comparison of clinical and lung function parameters between underweight patients 
(body mass index [BMI] < 21 kg/m2) and patients with BMI ≥ 21 kg/m2. 
Data are presented as means ± standard deviation or numbers (%), as appropriate. 
* statistically significant (p <0.05) 
Abbreviations: BMI: body mass index; CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary 
disease; DLCO/VA: diffusing capacity of the lung for carbon monoxide per litre of alveolar volume; EQ-5D-5L: 
EuroQol questionnaire; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; HADS: 
Hospital Anxiety and Depression Scale; mMRC: modified Medical Research Council; Post: post-bronchodilator; 
pred: predicted; RV: residual volume; RV/TLC: ratio of residual volume to total lung capacity; TLC: total lung 
capacity; VAS: visual analogue scale.  
 
 
 
 
 
Parameter 
Patients with   
BMI < 21 kg/m2 
 (n=18) 
Patients with   
BMI ≥ 21 kg/m2 
(n=93) 
p-value 
Age, years 66.2 ± 7.4 68.0 ± 7.8 0.625 
Sex 
      Male 
      Female 
 
10 (55.6) 
8 (44.4) 
 
66 (71.0) 
27 (29.0) 
0.198 
Smoking history, pack-years 39.9 ± 25.8 44.7 ± 24.6 0.419 
Treated for COPD, years 7.6 ± 8.2 9.4 ± 7.3 0.197 
COPD exacerbations in the previous year 1.4 ± 2.2 1.2 ± 1.2 0.514 
mMRC dyspnoea scale 2.3 ± 1.0 1.9 ± 0.9 0.138 
CAT score 18.6 ± 6.2 17.8 ± 6.5 0.651 
Post FVC, % pred. 91.2 ± 21.3 90.8 ± 18.7 0.737 
Post FEV1, % pred. 43.0 ± 16.0 50.1 ± 14.7 0.058 
TLC, % pred. 129.7 ± 16.0 106.7 ± 24.3 <0.001* 
RV, % pred. 208.2 ± 61.5 149.9 ± 57.9 <0.001* 
RV/TLC, % pred. 152.8 ± 32.2 130.9 ± 30.3 0.004* 
DLCO/VA, % pred. 47.7 ± 13.7 74.7 ± 21.8 <0.001* 
Charlson comorbidity index 1.6 ± 0.9 1.8 ± 1.1 0.472 
HADS Anxiety score 5.9 ± 4.1 6.9 ± 4.1  0.507 
HADS Depression score 7.3 ± 2.4 7.3 ± 3.7 0.803 
EQ-5D-5L index value 0.7 ± 0.2 0.7 ± 0.2 0.885 
EQ-5D-5L VAS 55.3 ± 15.0 58.4 ± 15.3 0.447 
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5.8. Evaluation of physical performance in patients with different forms of 
nutritional abnormality 
The average values for the 4MGS, 6MWD and daily step count for patients in four BMI 
categories – underweight (BMI <21 kg/m2), normal weight (BMI ≥21, <25 kg/m2), 
overweight (BMI ≥25, <30 kg/m2) and obese (BMI ≥30 kg/m2) are presented in Table 16.  
No significant differences were observed in the physical performance between patients in 
different BMI categories. 
 
  
Table 16. Physical performance of the study population in relation to the nutritional status. 
 Data are presented as means ± standard deviation. 
* BMI <21 kg/m2 
# BMI ≥21, <25 kg/m2 
§ BMI ≥25, <30 kg/m2 
$ BMI ≥30 kg/m2 
Abbreviations: BMI: body mass index; 4MGS: 4-metre gait speed; 6MWD: 6-minute walk distance.  
 
 
Parameter 
 
Underweight 
patients* 
(n=18) 
 
 
Patients with 
normal weight #  
 (n=31) 
 
 
Overweight 
patients § 
 (n=27) 
 
Obese 
patients $ 
(n=35) 
 
p-value 
4MGS, m/s 0.85 ± 0.23 0.90 ± 0.24 0.88 ± 0.24 0.92 ± 17 0.728 
6MWD, m 348 ± 140 379 ± 115 386 ± 123 379 ± 112 0.759 
Physical activity, 
steps/day 7104 ± 5356 8074 ± 4701 9295 ± 5383 7582 ± 3909 0.412 
    
 
63 
 
5.9. Association between physical activity and severity of COPD 
The association between physical activity expressed as a daily step count and selected 
parameters related to the severity of COPD (i.e. lung function parameters, symptoms severity 
scores, frequency of exacerbations) was evaluated using the Spearman correlation analysis 
(Table 17, Figure 13).  
A strong negative and a moderate positive correlation was observed between daily step count 
and the mMRC dyspnoea level (Spearman correlation coefficient rho = -0.664, p<0.001), and 
the FEV1 (rho = 0.467, p<0.001), respectively (Fig 13A and 13B). The correlation for the 
RV/TLC was moderate, negative (rho = -0.400, p<0.001) (Fig 13C), and for the DLCO/VA 
weak, positive (rho = 0.312, p=0.001) (Fig 13D). Previous exacerbations and the CAT score 
both showed weak negative correlation with daily step count (Fig 13E and 13F). 
 
 
Table 17. Correlations between daily step count and parameters of COPD severity. 
 * statistically significant (p <0.05) 
Abbreviations: CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary disease; DLCO/VA: 
diffusing capacity of the lung for carbon monoxide per litre of alveolar volume; FEV1: forced expiratory volume 
in one second; mMRC: modified Medical Research Council; Post: post-bronchodilator; pred: predicted; 
RV/TLC: ratio of residual volume to total lung capacity.  
 
 
 
 Daily step count  
 Spearman correlation coefficient rho, p-value 
Post FEV1, % pred. 0.467, p<0.001* 
RV/TLC, %  -0.400, p<0.001* 
DLCO/VA, % pred. 0.312, p=0.001* 
COPD exacerbations in the previous year -0.308, p=0.001* 
mMRC dyspnoea level -0.664, p<0.001* 
CAT score -0.372, p<0.001* 
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Figure 13. Correlations between daily step count and parameters of COPD severity. 
Abbreviations: CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary 
disease; DLCO/VA: diffusing capacity of the lung for carbon monoxide per litre of alveolar 
volume; FEV1: forced expiratory volume in one second; mMRC: modified Medical Research 
Council; Post: post-bronchodilator; pred: predicted; RV/TLC: ratio of residual volume to total 
lung capacity.  
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5.10. Correlation between physical activity and simple tests of muscle 
function / mass 
The results of the Spearman correlation analysis for physical activity expressed as a daily step 
count and simple tests of muscle function (4MGS, 6MWD, 30-second chair stand test, timed 
up and go test, handgrip strength) and several indicators of muscle mass (FFMI, CC, AMA, 
RFCSA) are presented in Table 18 and Figure 14.  
A strong correlation was found between daily step count and the 6MWD (rho = 0.684, 
p<0.001) (Fig 14A), and a moderate correlation between daily step count and the 4MGS (rho 
= 0.464, p<0.001) (Fig 14B). The correlation for the 30-second chair stand test was moderate, 
positive (rho = 0.402, p<0.001) (Fig 14C), and for the timed up and go test moderate, 
negative (rho = -0.463, p<0.001) (Fig 14D). Furthermore, the FFMI and daily physical 
activity showed a weak correlation (rho = 0.210, p=0.027) (Fig 14E).  
No significant correlations were found between daily step count and the handgrip strength, 
CC, AMA and RFCSA, respectively (Table 18).  
 
Table 18. Correlations between daily step count and parameters of muscle function / mass.  
 * statistically significant (p <0.05) 
 
 Daily step count  
 Spearman correlation coefficient rho, p-value 
4-metre gait speed, m/s  0.464, p<0.001* 
6-minute walk distance, m   0.684, p<0.001* 
30-second chair stand test, number of rises 0.402, p<0.001* 
Timed up and go test, s -0.463, p<0.001* 
Handgrip strength, kg 0.129, p=0.176 
Fat-free mass index, kg/m2 0.210, p=0.027* 
Calf circumference, cm 0.167, p=0.080 
Arm muscle area, cm2 0.163, p=0.088 
Rectus femoris cross-sectional area, cm2 0.134, p=0.161 
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Figure 14. Significant correlations between daily step count and parameters of muscle 
function / mass.  
Abbreviations: FFMI: fat-free mass index; 4MGS: 4-metre gait speed; 6MWD: 6-minute 
walk distance. 
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5.11. Association between physical activity, body composition and health-
related quality of life  
The Spearman rank correlation test was used to determine the association between physical 
activity, FFMI and health-related quality of life, which was assessed with the EQ-5D-5L 
index value and the EQ-5D-5L VAS (Table 19).  
Physical activity expressed as a daily step count showed a moderate positive correlation with 
the EQ-5D-5L index value (rho = 0.403, p<0.001) (Fig 15A), and a weak positive correlation 
with the EQ-5D-5L VAS score (rho = 0.308, p=0.001) (Fig 15B).  
No correlation was found between FFMI and the health-related quality of life measures 
(Table 19). 
 
 Table 19. Correlations between physical activity, fat-free mass index and health-related 
quality of life measures. 
 * statistically significant (p <0.05) 
Abbreviations: EQ-5D-5L: EuroQol questionnaire; VAS: visual analogue scale. 
 
 
 
 EQ-5D-5L index value EQ-5D-5L VAS 
 
Spearman correlation 
coefficient rho, p-value 
Spearman correlation 
coefficient rho, p-value 
Physical activity, steps/day  0.403, p<0.001* 0.308, p=0.001* 
Fat-free mass index, kg/m2 0.115, p=0.231 0.148, p=0.121 
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Figure 15. Correlations between physical activity and the health-related quality of life 
measures. 
Abbreviations: EQ-5D-5L: EuroQol questionnaire; VAS: visual analogue scale. 
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5.12. Association between physical activity, body composition and anxiety / 
depression 
Based on the HADS Anxiety score, 42 (38%) patients had some degree of anxiety (HADS 
Anxiety score ≥ 8): 26 (23%) patients scored in the range of mild anxiety, 8 (7%) moderate, 
and 8 (7%) severe anxiety. Regarding symptoms of depression, 48 (43%) patients manifested 
clinically significant depression (HADS Depression score ≥ 8): 26 (23%) mild, 19 (17%) 
moderate, and 3 (3%) severe depression.  
No significant correlations were found between daily step count and HADS Anxiety score 
and HADS Depression score, respectively (Table 20). Similarly, there were no correlations 
between FFMI and measures of anxiety/depression.  
 
 
Table 20. Correlation between physical activity, fat-free mass index and psychological status. 
 Abbreviations: HADS: Hospital Anxiety and Depression Scale.  
 
 
 HADS Anxiety score HADS Depression score 
 
Spearman correlation 
coefficient rho, p-value 
Spearman correlation coefficient 
rho, p-value 
Physical activity, steps/day  -0.003, p=0.975 -0.168, p=0.077 
Fat-free mass index, kg/m2 -0.109, p=0.255 -0.089, p=0.353 
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6.  DISCUSSION 
The results of the presenting study indicate that in the population of ambulatory patients with 
moderate to very severe COPD, patients with poor physical performance have deficient 
nutritional status, which manifested dominantly with lower parameters of muscle/bone tissue 
and serum protein levels. There were no significant differences in the BMI and parameters 
related to fat tissue between patients with poor and normal physical performance. In the 
multivariate analysis the variables that were independently and significantly associated with 
poor exercise capacity were older age, previous exacerbations, lung hyperinflation, reduced 
lung diffusion capacity and dyspnoea level; and likewise, older age, reduced lung diffusion 
capacity and dyspnoea level were independently associated with poor physical activity. 
However, none of the nutritional parameters were identified as independently related to poor 
physical performance. 
 
6.1. Discussion regarding the general aim of the research  
Comparison of nutritional status / body composition in COPD patients with 
poor and normal physical performance  
Patients with COPD apart from respiratory symptoms often develop extrapulmonary 
manifestations of the disease, some of them being nutritional alterations and body 
composition changes [96, 139]. Furthermore, physical inactivity is highly prevalent in patients 
with COPD, which is closely associated not only with the ventilatory limitation, but also with 
the peripheral muscle loss and dysfunction [115, 129].  
The general aim of the presenting research was to compare nutritional status and body 
composition in COPD patients with poor and normal physical performance, which was 
assessed in three different ways – evaluation of exercise capacity by the 6MWD, 
measurement of gait speed by the 4MGS test, and objectively measured physical activity 
expressed as average daily step count. According to our results patients with poor physical 
performance determined by any of these three methods had deficient nutritional status in 
terms of reduced MNA score and several indicators of skeletal muscle mass – lower LMI and 
FFMI, as well as smaller CC, MAMC and AMA (Table 8, 11, 13). Additionally, patients with 
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poor exercise capacity (i.e. 6MWD ≤ 350 m) and those with slow gait speed (i.e. 4MGS < 0.8 
m/s) also had reduced DEXA parameters of bone tissue (i.e. BMC, BMD, T-score) (Table 8 
and 11), which might have been influenced by a higher proportion of women in both “poor 
exercise capacity” and “slow gait speed” groups compared to the respective “normal” groups 
(Table 7 and 10). Namely, women are more prone to increased loss of bone tissue with 
ageing than men, especially in the postmenopausal period [171].  
Although patients with poor physical activity (i.e. ≤ 7128 steps/day) also had lower BMD and 
T-score in comparison to patients with normal physical activity, this trend did not reach 
statistical significance (p=0.07), what is somewhat surprising considering that a significant 
difference was observed in the serum concentration of vitamin D, which is very important in 
bone metabolism. Patients with poor physical activity had significantly lower mean serum 
vitamin D concentration (Table 13), nevertheless, the causal relationship between vitamin D 
and physical activity level in this research could not be established because of the cross-
sectional study design, but the association might be bidirectional. Namely, vitamin D may 
improve physical performance, especially in the elderly population, through its function in 
musculoskeletal system [172, 173]. On the other hand, patients with more outdoor physical 
activities have more sun exposure that stimulates the production of vitamin D in the skin, 
which is the main source of vitamin D in humans. It is of note, however, that although 
patients with normal physical activity had significantly higher serum vitamin D levels, even 
77% of study population was vitamin D deficient (serum vitamin D concentration < 50 
nmol/L), and the mean vitamin D levels for the entire study population as well as in all “poor” 
and “normal” physical performance groups were constantly in the range of deficiency (Table 
6, 8, 11, 13), which is consistent with the previously reported high prevalence of vitamin D 
deficiency in the general elderly population [173, 174].  
Serum proteins may give additional information on nutritional status, and in this study 
albumin and prealbumin levels were explored. Since both proteins belong to the negative 
acute phase reactants, the concentration of which fall during inflammation [111], serum levels 
of hs-CRP were also determined as a measure of systemic inflammation. Patients with poor 
exercise capacity had significantly lower serum albumin and prealbumin concentrations, and 
patients with poor physical activity had lower prealbumin levels (Table 8 and 13). No relation 
was found between hs-CRP and physical performance.  
It is important to note that there were no differences in the BMI, FMI, fat proportion, waist 
and hip circumference, waist-to-hip ratio and TSF between patients with poor and normal 
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physical performance (Table 8, 11, 13), which suggests that nutritional differences that were 
observed in relation to physical performance are mainly reserved to the muscle/bone mass and 
protein status, and not to the fat tissue. This is not surprising having in mind the central role of 
the musculoskeletal system in body movements. These results are also in line with previously 
published studies using BIA in the body composition evaluation in COPD patients that found 
a positive correlation between FFMI and the 6MWD [153, 175]. However, the advantage of 
this research is that in the assessment of nutritional status several different methods were used 
- anthropometry, serum biomarkers, MNA questionnaire, and most importantly the DEXA, 
which is considered a reference method for the measurement of body composition in the 
clinical settings and is superior to more accessible and more used BIA [176].  
Besides nutritional parameters the comparison of patients with poor and normal physical 
performance also included demographic variables and parameters related to the lung disease, 
health-related quality of life and psychological status. Irrespective of which method was used 
in the assessment of physical performance (6MWD, 4MGS or daily step count), patients with 
poor physical performance were older, had worse lung function (i.e. more severe airflow 
obstruction manifested as the lower FEV1, lung hyperinflation demonstrated by the higher RV 
and RV/TLC, reduced lung diffusion capacity, more pronounced hypoxemia), higher 
symptom burden, more frequent exacerbations, and worse health-related quality of life (Table 
7, 10, 12). These data are consistent with the findings of other authors, who reported higher 
prevalence of physical inactivity with increasing COPD severity [116, 155], and related 
physical inactivity / exercise intolerance to multiple negative clinical consequences including 
functional limitation, impaired health-related quality of life, higher exacerbation and hospital 
admission rate, and increased mortality [117-120, 156].  
In order to detect which variables are independently associated with poor physical 
performance, we performed the multivariate analysis. Two multivariate models were built, the 
first one with poor exercise capacity (i.e. 6MWD ≤ 350 m) as a dependent variable, and the 
second one with poor physical activity (i.e. ≤ 7128 steps/day) as a dependent variable. Since a 
very strong correlation was found between 6MWD and 4MGS, which is in accordance with 
previously published data [169, 177], separate multivariate analysis for slow gait speed was 
not justified and therefore not performed. The variables that were independently and 
significantly associated with poor exercise capacity in the first multivariate model were older 
age, previous exacerbations, lung hyperinflation, reduced lung diffusion capacity and 
increased level of dyspnoea. Similarly, the second multivariate model identified older age, 
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decreased lung diffusion capacity and higher dyspnoea level as independently associated with 
poor physical activity. Although several nutritional parameters (e.g. MNA score, FFMI, LMI, 
AMA, prealbumin) showed a significant association with poor physical performance in the 
univariate analysis, after adjusting for age, sex, and parameters of lung function and 
symptoms severity in the multivariate models this significance was lost and finally none of 
the nutritional parameters were independently associated with poor physical performance. 
This suggests that age, air trapping, gas transfer and dyspnoea have a stronger relation to 
physical performance, and that the body composition alterations observed in patients with 
different levels of physical performance are secondary and influenced by other factors, 
probably related to the disease itself and to the process of ageing.  
 
6.2. Discussion regarding the specific aims of the research 
6.2.1. Factors associated with malnutrition in patients with COPD 
Although the term malnutrition includes both undernutrition and overnutrition (as previously 
explained in section 1.2.), here it has been used in its narrow sense of meaning referring to the 
undernutrition and underweight. Reduced body weight and low BMI, largely attributed to the 
loss of skeletal muscle mass, have long been recognised as independent predictors of health-
care use and mortality in COPD [101, 102, 142]. On the other hand, for patients with COPD 
being overweight or obese seems to have a protective effect on survival. Namely, overweight 
and obese COPD patients have a lower risk of all-cause mortality when compared not only to 
underweight patients, but also to those with normal weight, which was named “obesity 
paradox” [101, 102, 178]. 
As it was explained in section 1.2., studies on COPD frequently use a BMI <20 or <21 kg/m2 
when defining underweight instead of <18.5 kg/m2 (recommended by the WHO for the 
general population), since a higher mortality has been observed in COPD patients below these 
values [101, 102]. The cut-off BMI <21 kg/m2 for underweight patients with COPD is also 
recommended by the ATS/ERS [103], and it was applied in the presenting research.  
We identified only 18 (16%) underweight patients, while the proportion of overweight and 
obese patients was quite high (24% and 32%, respectively) (Figure 9A). Furthermore, FFM 
depletion, defined as FFMI <16 kg/m2 for men and <15 kg/m2 for women, was detected in 4% 
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of male and 37% of female patients in our study population (Figure 10). According to the 
previously published data underweight and FFM depleted patients make up 20-40% of the 
COPD population, with increasing prevalence in advanced stages of disease, especially in 
women [140-142]. Lower prevalence of underweight in our population may be explained by 
the fact that the study was conducted in outpatients with the mean postbronchodilator FEV1 
49% and the majority of patients were in the GOLD 2 and 3 category of airflow limitation 
(Figure 7). Due to the study design and exclusion criteria the most fragile patients with very 
severe COPD who are bedridden or extremely inactive could not have been included in this 
research, and in such population a prevalence of underweight is expected to be higher.  
On the other hand, a high proportion of overweight/obese patients in our research concurs 
with some previous studies that reported a rising prevalence of overweight and obesity in 
COPD, especially in mild-to-moderate disease – in the study by Eisner et al. [146] in a COPD 
cohort with a mean FEV1 58% there were 20% overweight and 54% obese patients, and in the 
study by Cecere et al. [148] 32% of patients were overweight (mean FEV1 50%) and 38% 
obese (mean FEV1 55%). 
When underweight patients were compared with the rest of the study population, the 
parameters that were significantly different between them were TLC, RV, RV/TLC (higher in 
underweight) and DLCO/VA (lower in underweight) (Table 15), which suggests more severe 
lung hyperinflation and reduction in lung diffusion capacity. Although imaging techniques 
(e.g. chest CT scan) were not used in our study and therefore the degree of emphysema could 
not have been precisely measured, lung function measurements reflecting lung hyperinflation 
and decreased lung diffusion capacity provide a good estimate of the extent of emphysema 
[179]. Our results are in accordance with previously published data indicating that low body 
weight in COPD is related to the degree of emphysema [180]. In our study underweight 
patients also had more severe airflow limitation (i.e. lower FEV1), however this difference did 
not reach statistical significance (p=0.058).  
Due to the small number of underweight patients the multivariate analysis in prediction of 
malnutrition would not be conclusive and was therefore not performed.  
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6.2.2. Physical performance in patients with different forms of nutritional 
abnormality  
Based on the previous observations suggesting bidirectional relation between physical 
performance and nutritional status, we explored and compared the physical performance of 
COPD patients in different BMI categories (underweight, normal weight, overweight, and 
obese). Contrary to some of the existing evidence, the differences in the 6MWD, 4MGS and 
daily step count between patients in different BMI categories in our study were not significant 
(Table 16). On the other hand, Ischaki et al. [175] found a positive correlation between 
6MWD and both BMI and FFMI. In addition, in the study by Lan et al. [181] underweight 
patients with COPD had impaired exercise capacity, and the additional strengths of this study 
are that it was conducted in a lung function-matched patients (the mean FEV1 was similar in 
the underweight, normal-weight, and overweight group) and that in the assessment of exercise 
capacity cardiopulmonary exercise test was used instead of 6MWT. In our research 
underweight patients also had the worst exercise capacity (i.e. the lowest mean 6MWD), 
though this trend did not reach statistical significance. 
Regarding gait speed, Abbatecola et al. [150] showed in a population of older COPD patients 
that participants with the slowest gait speed apart from being older and having worse lung 
function, also had higher BMI and FM, as well as lower lean-to-fat ratio. Additionally, among 
body composition markers FM was the only independent determinant of walking speed [150]. 
However, due to the methodological differences in the study design a comparison of the 
results of this study and our study is limited. Firstly, Abbatecola et al. [150] calculated the 
gait speed by dividing 6MWD by time, and we performed 4MGS test. Secondly, the 
population in a study by Abbatecola et al. [150] were patients admitted for pulmonary 
rehabilitation and in general their mobility was better (the mean values for the three walking 
speed tertiles were 0.93, 1.1 and 1.43 m/s, respectively) than in our study population (mean 
walking speed 0.89 m/s, range 0.33-1.35 m/s). Thirdly, in the body composition analysis 
Abbatecola et al. [150] used BIA instead of DEXA that was used in our study, and they used 
absolute values for FM and FFM, while we calculated FMI and FFMI by dividing the FM and 
FFM, respectively, by height squared.  
When it comes to physical activity, Monteiro et al. [182] demonstrated worse physical 
activity in the daily life in obese COPD patients compared to underweight and normal-weight 
patients. In our study obese and underweight patients had the lowest daily step count, and 
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overweight patients the highest, nevertheless, these differences were not statistically 
significant. 
 
6.2.3. Association between physical activity and severity of COPD  
It is well established that low physical activity is common in patients with COPD, what 
becomes even more evident with increasing severity of the disease, as discussed previously in 
sections 1.3. and 1.4. [115, 116, 155]. In order to investigate the association between physical 
activity and the severity of COPD in our patients, we looked for a correlation between daily 
step count and several parameters of lung function, symptoms severity scores and 
exacerbation frequency (Table 17).  
Existing evidence supports the association between physical activity and various lung 
function indicators of respiratory limitation in COPD, which includes airflow limitation, static 
and dynamic lung hyperinflation, reduced lung diffusion capacity with subsequent pulmonary 
gas exchange abnormalities, and respiratory muscle dysfunction [137, 183-187]. In line with 
previous studies our results indicate significant correlations between daily step count and 
several parameters of lung function – the correlation was moderate positive in the case of 
FEV1, indicator of airflow limitation (Fig 13B); moderate negative in the case of RV/TLC, 
marker of lung hyperinflation (Fig 13C); and weak positive for the DLCO/VA, representing 
lung diffusion capacity (Fig 13D). 
We also found a strong negative correlation between daily step count and the mMRC 
dyspnoea grade, which concurs with previously published data repeatedly demonstrating that 
physical activity is affected by the level of exertional breathlessness [137, 183]. 
Furthermore, previous findings suggest linear relationship between self-reported walking time 
and CAT score, a measure of symptom severity in COPD [119]. In our study a weak negative 
correlation was observed between CAT score and objectively measured physical activity (Fig 
13F). 
Exacerbations are unfavourable events in the course of COPD with multiple negative 
implications. Existing evidence suggest a bidirectional relation between physical activity and 
COPD exacerbations. Namely, due to worsening in respiratory symptoms patients are less 
active during exacerbations and shortly thereafter, moreover, frequent previous exacerbations 
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have been recognised as predictors of reduced physical activity in the future [184, 189]. On 
the other hand, higher level of physical activity may be protective and may prolong the time 
until the next exacerbation [157, 190]. In accordance with the previously published data, we 
found a weak negative correlation between the number of moderate/severe exacerbations in 
the previous year and a daily step count (Fig 13E). 
 
6.2.4. Correlation between physical activity and simple tests of muscle 
function / mass 
The assessment of physical activity is time consuming and requires additional equipment, 
which makes it impractical for its implementation in routine clinical practice. Hence, one of 
the aims of the present research was to evaluate whether some simple and rapid tests of 
physical performance exhibit a good correlation with objectively measured physical activity, 
and may potentially serve as surrogate methods for assessing physical activity.  
We found a strong positive correlation between daily step count and the 6MWD (Fig 14A), 
and a moderate positive correlation between daily step count and the 4MGS (Fig 14B). These 
results are in line with the findings of other authors demonstrating physical activity to be 
strongly related to the exercise capacity measured by the 6MWD on the one hand [183, 186, 
187], and moderately related to the walking speed on the other [177, 191].  
As it was discussed in section 1.3. 30-second chair stand test was developed for the 
assessment of lower extremity muscle strength in older people, while the timed up and go test 
is a reliable and valid method for quantifying mobility and balance in older people [126, 128]. 
Both tests are rapid and easy to perform, and we found that the 30-second chair stand test was 
in a moderate positive correlation with the daily step count (Fig 14C), and the timed up and 
go test in a moderate negative correlation (Fig 14D). These results contribute to the 
knowledge in this field, because there have not been any previously published studies 
investigating the correlation between physical activity and either of these two tests. The only 
comparable published data are for the sit-to-stand test, which is similar to the 30-second chair 
stand test with the main difference that the participant repeatedly rises from the chair without 
support from the hands for a duration of one minute instead of 30-seconds as in the 30-second 
chair stand test [126, 127]. In the study by van Gestel et al. [192] the number of stands in the 
sit-to-stand test showed moderate positive correlation with the daily step count in patients 
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with COPD. On the other hand, Albarrati et al. [193] demonstrated that the timed up and go 
test was inversely related to the 6MWD and FEV1, and directly related to the quality of life 
assessed by the St. George's Respiratory Questionnaire and to the symptoms severity assessed 
by the CAT score. However, until now there has not been any data available on the 
correlation between the timed up and go test and objectively measured physical activity. 
FFMI as an indicator of muscle and bone mass is expected to be related to physical 
performance. There are several studies available that explored the association between FFMI 
in patients with COPD and their exercise capacity measured by the 6MWD, and they found a 
positive correlation between them [153, 175]. However, the evidence on relation between 
FFMI and physical activity in patients with COPD is not so strong, because there is only one 
published study that investigated this subject and found a weak positive correlation between 
FFMI and physical activity level [191]. In accordance with this study, the FFMI and daily 
step count were also weakly correlated in our research (Fig 14E). 
As it was previously discussed in section 1.4., peripheral muscle dysfunction is present in 
about one-third of patients with COPD, even in those with mild disease, and has been 
associated with multiple negative implications, including exercise intolerance, increased 
health care use, reduced quality of life and increased mortality [129, 130, 145]. We evaluated 
muscle function in our COPD patients by measuring handgrip strength, and as an alternative 
to measuring quadriceps strength we used ultrasound imaging of the quadriceps muscle with 
measurement of the RFCSA. In contrast to some of the published data suggesting a weak to 
moderate correlation between handgrip strength / quadriceps strength and physical activity 
[186, 191, 194], we did not find significant correlations between daily step count and 
handgrip strength or RFCSA, respectively (Table 18). We also explored the association 
between daily step count and two anthropometric parameters related to the limb muscle mass 
(CC and AMA), but nor here no significant correlations were found (Table 18). The absence 
of statistically significant relation between physical activity and previously mentioned 
parameters of muscle strength/mass (i.e. handgrip strength, RFCSA, CC, AMA) in our research 
may be explained by the fact that physical activity was expressed as a daily step count and did 
not take into account the intensity of the activity, which is an important part of the effect of 
physical activity in building muscle mass and strength. 
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6.2.5. Association between physical activity, body composition and health-
related quality of life  
For patients with COPD the tendency of adopting a sedentary lifestyle is rising with 
increasing severity of the lung disease, moreover, physical activity substantially decreases 
with time across all severity stages of COPD, and this decline is paralleled by a worsening of 
health status and quality of life. [115, 116, 155]. Esteban et al. [117] have demonstrated that a 
reduction in time spent engaging in physical activity or maintaining a low level of activity 
may impair health-related quality of life, whereas an increase in physical activity level over 
time can improve quality of life parameters. Furthermore, average daily step count and 
functional capacity have been recognised as independent determinants of a health-related 
quality of life in patients with COPD [195]. Our results are in accordance with the previously 
published data: physical activity expressed as a daily step count showed a positive correlation 
with the quality of life parameters - moderate correlation with the EQ-5D-5L index value (Fig 
15A), and a weak correlation with the EQ-5D-5L VAS score (Fig 15B).  
On the contrary, the existing evidence for the relation between the muscle mass depletion and 
quality of life in COPD is not as straightforward. Namely, in the study by Verhage et al. [196] 
FFMI reduction did not show correlation with the health status, while in the study by Mostert 
et al. [197] depletion of FFM irrespective of body weight was associated with the impairment 
of quality of life. In our study no correlation was found between the FFMI and the health-
related quality of life measures (Table 19). 
 
6.2.6. Association between physical activity, body composition and 
anxiety/depression 
Based on the HADS score 38% of our study population had some degree of anxiety and 43% 
presented clinically significant depression. In the previously published studies the prevalence 
of depression in COPD patients ranged from 24% to 75%, depending on the severity of the 
pulmonary disease and the method used in the evaluation of psychological status [32, 198]. 
The existing evidence indicates that depressive COPD patients have worse lung function, 
greater dyspnoea, poorer quality of life, more exacerbations, and reduced exercise capacity 
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and physical activity [32, 158]. On the other hand, it has been suggested that increased 
anxiety in COPD patients was associated with higher levels of physical activity [199]. 
In our research patients with poor exercise capacity (6MWD ≤ 350 m) and those with slow 
gait speed (4MGS < 0.8 m/s) had significantly higher HADS Depression scores (Table 7 and 
10). In contrast to the published data, patients with poor physical activity (daily step count ≤ 
7128 steps/day) did not differ from the normal activity group in the symptomatology of 
depression (Table 12). Equally, the level of anxiety was not different in patients with poor 
physical performance determined by any of the three methods (i.e. 6MWD, 4MGS, and daily 
step count) (Table 7, 10 and 12).  
In line with these results, there were no significant correlations between daily step count and 
HADS Anxiety score and HADS Depression score, respectively (Table 20). Similarly, no 
correlations were found between the FFMI and measures of anxiety/depression in our study 
population (Table 20). 
Our data confirm that depression and anxiety are common problems in patients with COPD, 
however, these are complex disorders influenced by many factors, and their association with 
physical performance was only partially demonstrated in our research. 
 
6.3. Study limitations 
Several study limitations need to be addressed. Firstly, physical activity was assessed by 
measuring steps walked throughout the day and not a distance walked or energy expenditure. 
Because the step length of a person is related to a body height and legs length, the same 
distance walked by people of a different height may translate into a different number of steps. 
However, the same activity monitor that was used in our research has already been validated 
and proven accurate at measuring physical activity in patients with COPD, and it has been 
applied in multiple studies, including studies with populations other than COPD patients 
resulting in nearly 200 peer-reviewed publications [118, 137, 200]. 
Secondly, for each patient physical activity was assessed during 7±2 consecutive days and the 
study was conducted from February 2015 to June 2016, which included different seasons. 
Although according to some previously published data there is a trend of lower activity during 
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periods of the year with poor weather and lower temperatures, the seasonal variations of 
physical activity were not taken into account in this research [132, 201].  
Finally, the analysis of physical performance and nutritional status was not carried out 
separately for men and women. Even though the proportions of women in the “poor exercise 
capacity” and “slow gait speed” groups were higher than in the corresponding “normal” 
groups, female sex did not show significance in the multivariate analysis. Additionally, no 
association was found between female sex and poor physical activity, thus differences in the 
physical performance and accompanying alterations in the nutritional status of the study 
population cannot be ascribed to the variations in gender distribution.  
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7.  CONCLUSIONS 
1) In the population of patients with moderate to very severe COPD physical performance 
was assessed in three different ways – exercise capacity evaluated by the 6MWD, gait speed 
measured by the 4MGS test, and objectively measured physical activity expressed as average 
daily step count. Patients with poor physical performance determined by any of these three 
methods had deficient nutritional status in terms of reduced MNA scores and several 
indicators of skeletal muscle mass – lower LMI and FFMI, and smaller CC, MAMC and 
AMA. 
2) Patients with poor exercise capacity (i.e. 6MWD ≤ 350 m) and those with slow gait speed 
(i.e. 4MGS < 0.8 m/s) had significantly lower DEXA parameters of bone tissue - BMC, 
BMD, and T-score. Patients with poor physical activity (i.e. ≤ 7128 steps/day) also had 
reduced BMD and T-score, however, this trend did not reach statistical significance (p=0.07). 
3) Patients with poor exercise capacity had significantly lower serum albumin and prealbumin 
concentrations, and patients with poor physical activity had lower prealbumin and vitamin D 
levels. 
4) Vitamin D deficiency (serum vitamin D concentration < 50 nmol/L) was present in 77% of 
the study population and the mean vitamin D levels for the entire study population as well as 
in all “poor” and “normal” physical performance groups were constantly in the range of 
deficiency. 
5) Irrespective of which method was used in the assessment of physical performance (6MWD, 
4MGS or daily step count), patients with poor and normal physical performance did not differ 
in the BMI, FMI, fat proportion and fat mass-related anthropometric measurements (e.g. TSF, 
waist and hip circumference, waist-to-hip ratio). This suggests that the observed nutritional 
differences between patients at different levels of physical performance are mainly limited to 
the muscle/bone mass and protein status, and not to the fat tissue. 
6) Apart from the aforementioned nutritional differences, patients with poor physical 
performance were older, had worse lung function (i.e. more severe airflow obstruction 
manifested as the lower FEV1, lung hyperinflation demonstrated by the higher RV and 
RV/TLC, reduced lung diffusion capacity, more pronounced hypoxemia), higher symptom 
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burden (i.e. higher CAT score and mMRC dyspnoea level), more frequent exacerbations, and 
worse health-related quality of life (i.e. lower EQ-5D-5L index value and VAS score). 
7) Based on the results of the multivariate analysis, variables that were independently and 
significantly associated with poor exercise capacity were older age, previous exacerbations, 
lung hyperinflation, reduced lung diffusion capacity and higher dyspnoea level. Similarly, 
older age, reduced lung diffusion capacity and higher dyspnoea level were also independently 
associated with poor physical activity. However, none of the nutritional parameters showed an 
independent relation to physical performance in our study. This suggests that age and 
parameters associated with ventilatory limitation (i.e. air trapping, compromised gas exchange 
and dyspnoea) have a stronger relation to physical performance, and that the body 
composition alterations in patients with poor physical performance are secondary and 
influenced by other factors, most likely by the disease itself and by the process of ageing. 
8) In our study population only 16% of patients were underweight (BMI <21 kg/m2) while the 
proportion of overweight (BMI ≥25, <30 kg/m2) and obese patients (BMI ≥30 kg/m2) was 
relatively high (24% and 32%, respectively). When compared to the rest of the study 
population, underweight patients had more severe lung hyperinflation (i.e. higher TLC, RV, 
and RV/TLC) and reduced lung diffusion capacity (i.e. lower DLCO/VA).  
9) Patients in different BMI categories did not show significant differences in the 6MWD, 
4MGS or daily step count. 
10) Regardless of body weight, 37% of female patients and 4% of male patients in our study 
population were FFM depleted (FFMI <15 kg/m2 for women and <16 kg/m2 for men). 
11) Physical activity expressed as a daily step count showed significant correlations with 
several parameters of lung function – the correlation was moderate positive in the case of 
FEV1, indicator of airflow limitation; moderate negative in the case of RV/TLC, marker of 
lung hyperinflation; and weak positive for the DLCO/VA, representing lung diffusion 
capacity. The strongest negative correlation was found between daily step count and the 
mMRC dyspnoea level. Exacerbations in the previous year and the CAT score both showed 
weak negative correlation with daily step count. 
12) Several simple and rapid tests of muscle function/mass demonstrated significant 
correlation with objectively measured physical activity. A strong correlation was found 
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between daily step count and the 6MWD, and a moderate correlation between daily step count 
and the 4MGS, the 30-second chair stand test, and the timed up and go test, respectively. 
Furthermore, the FFMI and daily step count showed a weak correlation. 
13) Physical activity showed a positive correlation with the quality of life parameters – 
moderate correlation with the EQ-5D-5L index value, and a weak correlation with the EQ-
5D-5L VAS score.  
14) No correlation was found between the FFMI and the health-related quality of life 
measures. 
15) Based on the HADS 38% of our COPD patients had some degree of anxiety and 43% 
manifested clinically significant depression. Patients with poor exercise capacity and those 
with slow gait speed had significantly higher HADS Depression scores. However, patients 
with poor physical activity did not differ from the normal activity group in the psychological 
status, and consequently no significant correlations were found between physical activity and 
measures of anxiety/depression. 
16) No correlations were observed between the FFMI and measures of anxiety/depression in 
our study population.  
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8.  ABSTRACT 
Physical inactivity and skeletal muscle mass wasting are frequent findings in patients with 
chronic obstructive pulmonary disease (COPD). The aim of the study was to compare 
nutritional status and body composition in COPD patients with poor and normal physical 
performance, which was assessed in three different ways – exercise capacity evaluated by the 
6-minute walk test, gait speed measured by the 4-metre gait speed test and physical activity 
expressed as average daily step count. In the population of 111 patients with moderate to very 
severe COPD, those with poor physical performance were older, had worse lung function, 
higher symptom burden, more frequent exacerbations, worse health-related quality of life, and 
deficient nutritional status, which manifested dominantly with lower parameters of 
muscle/bone tissue and serum protein levels. There were no significant differences in the 
body-mass index and parameters related to fat tissue. In the multivariate analysis the variables 
that were independently and significantly associated with poor exercise capacity were older 
age, previous exacerbations, lung hyperinflation, reduced lung diffusion capacity and higher 
dyspnoea level. Likewise, older age, reduced lung diffusion capacity and dyspnoea level were 
independently associated with poor physical activity. However, none of the nutritional 
parameters were independently related to poor physical performance. 
 
Keywords: chronic obstructive pulmonary disease; nutritional status; body composition; 
physical activity; exercise capacity; gait speed; lung function. 
 
Evaluation of nutritional status and physical performance in patients with chronic 
obstructive pulmonary disease (Zinka Matković, 2018) 
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9.  SAŽETAK 
Tjelesna neaktivnost i gubitak skeletne mišićne mase su česti u bolesnika s kroničnom 
opstrukcijskom bolešću pluća (KOPB). Cilj istraživanja je bio usporediti nutritivni status i 
tjelesni sastav u KOPB bolesnika sa smanjenom i normalnom fizičkom sposobnošću koja je 
procijenjena na tri različita načina – tjelesnom kondicijom na temelju 6-minutnog testa hoda, 
brzinom hoda mjerenom testom brzine hoda na 4 metra i tjelesnom aktivnošću izraženom 
prosječnim dnevnim brojem koraka. U populaciji od 111 bolesnika s umjereno teškim do vrlo 
teškim KOPB-om, bolesnici sa smanjenom fizičkom sposobnošću su bili stariji, imali lošiju 
plućnu funkciju, izraženije simptome, češće egzacerbacije, slabiju kvalitetu života i lošiji 
nutritivni status što se u prvom redu manifestiralo nižim vrijednostima parametara mišićno-
koštane mase i nižim vrijednostima serumskih proteina. Nije bilo značajne razlike u indeksu 
tjelesne mase niti u parametrima koji se odnose na masno tkivo. Multivarijantnom analizom je 
utvrđeno da su starija dob, prethodne egzacerbacije, hiperinflacija pluća, smanjen difuzijski 
kapacitet pluća i viši stupanj zaduhe nezavisno i statistički značajno povezani sa smanjenom 
tjelesnom kondicijom. Jednako tako su starija dob, smanjen difuzijski kapacitet pluća i viši 
stupanj zaduhe bili nezavisno povezani sa smanjenom tjelesnom aktivnošću. Nijedan 
nutritivni parametar nije pokazao nezavisnu povezanost sa smanjenom fizičkom sposobnošću. 
 
Ključne riječi: kronična opstrukcijska bolest pluća; nutritivni status; tjelesni sastav; tjelesna 
aktivnost; tjelesna kondicija; brzina hoda; plućna funkcija. 
 
Procjena nutritivnog statusa i fizičke sposobnosti bolesnika s kroničnom opstrukcijskom 
bolešću pluća (Zinka Matković, 2018.) 
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